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1. INTRODUCTION AND PURPOSE OF THE STUDY 
 
1.1. Epidemiology of lung cancer 
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death 
worldwide. Lung cancer accounted for 13% (1.6 million) of the total cancer cases and 18% 
(1.4 million) of the deaths globally in 2008 (Jemal et al. 2008). In the United States, it was 
estimated that there were 215,020 new lung cancer cases diagnosed and 161,840 deaths 
(American Cancer Society 2004). In Europe, lung cancer accounted for 12% of 
approximately 3.2 million new cancer cases, and 19.7% (334,800) of cancer-related deaths 
in the year of 2006 (Ferlay et al. 2007). 
Figure 1.1. Age-standardized lung cancer incidence rates (Ferlay et al. 2010) 
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Lung cancer is rapidly emerging as a major cause of mortality in the Middle East, Africa, 
and Asia as well. In Japan, 71,228 annual cancer-related deaths were attributed to lung 
cancer. During 2005, approximately 500,000 lung cancers were diagnosed in China (Yang 
et al. 2005) and death rates attributable to this disease were expected to increase 
substantially over the next several decades (Zhang et al. 2003).  
In Vietnam, lung cancer was the second most common cancer with 20,659 new cases and 
17,583 deaths annually (Jemal et al. 2008).  
 
1.2. Smoking and lung cancer 
Smoking accounts for 80% of the worldwide lung cancer burden in males and at least 50% 
of the burden in females (Ezzati et al. 2003). In the United States, approximately 80% of 
lung cancer deaths in men and women are due to tobacco abuse. Since 1965, the 
prevalence of smoking in the United States has declined significantly (Giovino et al. 2002). 
Jemal et al. observed that smoking prevalence and lung cancer death rates in the United 
States correlate inversely with state tobacco control efforts (Jemal et al. 2004).  
In the European Union, prevalence of smoking varies among different populations but dose 
coincide with low socioeconomic status, particularly in women. Women started smoking 
several decades later than males. Thus, lung cancer rates in females are increasing in many 
countries except the United States, Canada, the United Kingdom, and Australia, where 
they are plateau (Bray et al. 2010).  
Despite their lower prevalence of smoking (less than 4% adult smokers), Chinese females 
have higher lung cancer rates (21.3 cases per 100,000 females) than those in certain 
European countries such as Germany (16.4 cases per 100,000) and Italy (11.4 cases per 
100,000), with an adult smoking prevalence of about 20%. The relatively high burden of 
lung cancer in women is thought to reflect indoor air pollution from unventilated coal-
fueled stoves and from cooking fumes in China (Lam et al. 2004). 
In men, lung cancer death rates are decreasing in most Western countries, including many 
European countries, North America, and Australia, where the tobacco epidemic peaked by 
the middle of the last century. However, lung cancer rates are increasing in countries such 
as China and several other countries in Asia and Africa. In these countries, the epidemic of 
smoking has been established more recently and smoking prevalence continues to either 
increase or show signs of stability (Youlden et al. 2008). 
3 
 
The risk of lung cancer is related to duration as well as intensity of smoking. In general, 
the evolving patterns of lung cancer appear attributable at least in part to filters, tar content, 
and other variations in tobacco blends implemented to produce a more palatable nicotine 
delivery system. A hospital-based case control study carried out in the National Cancer 
Institute in Hanoi, investigating the role of tobacco and cancers, found that ‘water pipe’ 
smoking, a traditional and very popular type of smoking in the past and during the 
Vietnam war, is also strongly related to lung and superior aero-digestive tract cancer 
(Pham HA et al. 1999).  
Peto et al. reported a 16-fold increase in cumulative lung cancer risk in persistent smokers; 
this risk is doubled for individuals who initiate smoking before age 15 (Peto et al. 2000). 
Tobacco abuse has global economic, social, and medical ramifications. Overall, the trends 
in lung cancer incidence and mortality reflect tobacco consumption in various countries. 
Presently, China is the largest producer and consumer of tobacco products. Nearly 70% of 
males and 5% of females age 15 years and older are smokers. A total of 320 million 
Chinese smokers constitute approximately one third of all smokers worldwide. In China, 
the average daily consumption of cigarettes rose from one in 1950 to ten in 1990, a rate 
that was similar to that seen in the United States between 1910 and 1950. In addition, the 
prevalence of passive smoking in China exceeds 50%. Much of this exposure occurs in the 
home among women and children. As a result of current tobacco exposure, the incidence 
of lung cancer in China will increase dramatically during the next several decades, with 
predicted death rates attributable to tobacco approaching 3 million by the year of 2050. 
Similar trends will be occurring in other Asian countries, such as Vietnam and Taiwan 
(Zhang et al. 2003).  
As a country with a very high level of tobacco production and consumption, the cultivated 
surface for tobacco plants in Vietnam was about 24,000 hectares and tobacco production 
represented about 2 billion packs of cigarettes. These were mainly sold in the domestic 
market and the estimated annual level of consumption was about 600 cigarettes per capita 
(Hoang et al. 1995).  
The results of a survey in 1995 showed that 73.4% of males and 3.9% of females are 
smokers. The onset of smoking was at a young age: 70% of smokers began before the age 
of 25 years (Pham XD et al. 1995).  
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Levy et al. projected that a tenfold increase in cigarette tax would decrease smoking by 
30% during the next three decades in Taiwan (Levy et al. 2005). Similar projections have 
been published regarding the potential impact of cigarette taxation on smoking prevalence 
in Vietnam.  
Other known risk factors for lung cancer include exposure to several occupational and 
environmental carcinogens such as asbestos, arsenic, radon, and polycyclic aromatic 
hydrocarbons (Ginsberg et al. 2004). 
 
1.3. Pathology of lung cancer (Appendix A). 
1.3.1. Adenocarcinoma 
Adenocarcinomas were most common histological type of lung cancer. They are often 
located in the periphery of the lung and in the smaller airways. The precursor lesion for 
pulmonary adenocarcinoma is considered to be atypical alveolar hyperplasia (AAH). AAH 
frequently measures less than 5 mm in diameter, and is composed of atypical type II 
pneumocytes proliferating on an alveolar wall that is either normal in thickness or altered 
by inactive fibrous scarring. There is a histological spectrum between AAH and small non-
mucinous bronchioloalveolar carcinoma. These neoplasms are difficult to differentiate by 
cytological, histological, and genetic techniques. Lesions 5mm in diameter or less are 
usually made up of relatively small cells with limited nuclear atypia in comparison to 
larger lesions, which exhibit progressively more abnormal cells. The frequency and rate of 
progression from AAH to cancer is considered to be quite low, in the range of 1% to 5% 
over a period of years (Nakanishi et al. 1990). 
1.3.2. Bronchioloalveolar carcinoma 
Bronchioloalveolar carcinoma (BAC) is found in mucinous and non-mucinous variants. 
The mucinous type is characterized by the growth of malignant mucus containing goblet 
cells on the surface of alveolar walls. As such, it is often characterized by pools of mucous, 
and be associated with the so-called colloid variant of adenocarcinoma in which mucous is 
predominant over tumor cells. Mucinous BAC has a tendency to be multifocal and fatal. 
Non-mucinous BAC is composed of type II pneumocytes or Clara cells exhibiting nuclear 
anaplasia and pleomorphism greater than AAH, but less than other types of 
adenocarcinoma. The malignant cells spread over the alveolar walls in a monolayer, which 
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presents a barrier to gas exchange in the affected alveolar sac, leading to right to left 
intrapulmonary shunt (Lynch et al. 2004). 
1.3.3. Large cell carcinoma 
Large cell carcinomas are composed of large cells without cytoplasmic differentiation, and 
account for approximately 15% of all lung cancers. With more extensive sampling and 
electron microscopy, many undifferentiated large cell carcinomas can be classified more 
appropriately as poorly differentiated adenocarcinoma or, rarely, squamous cell carcinoma. 
The prognosis of large cell undifferentiated carcinoma is similar to that of adenocarcinoma 
and, in most clinical trials; the two histological types are grouped together. Large cell 
carcinoma show a partial neuroendocrine phenotype recognized from carcinoid histology, 
immunostaining for chromogranin A or synaptophysin, or the ultrastructural demonstration 
of dense core granules. When accompanied by necrosis, high mitotic rate, and tumor 
necrosis, these carcinomas are associated with a poor prognosis (Chan et al. 1995, Moro et 
al. 1994). 
1.3.4. Squamous cell carcinoma 
Squamous cell carcinoma classically arises in proximal segmental bronchi via progression 
through stages of dysplasia. In its earliest form (carcinoma in situ), malignant squamous 
cells spread over the bronchial surface, often involving submucosal glands, without 
invasion through the basement membrane. Because there is exfoliation of the malignant 
cells from the bronchial surface, squamous cell carcinoma can be detected by cytological 
examination at its earliest stage. Occasionally this is before it is evident on chest x-ray, 
because of its origin in the electron-dense bronchi, which render them radiographically 
occult. With further growth, squamous cell carcinoma invades the basement membrane and 
extends into the parenchyma and bronchial lumen, producing obstruction with resultant 
atelectasis or pneumonia. Histologically, squamous cell carcinoma is composed of sheets 
of epithelial cells with individual cell keratinization, intercellular bridges, or pearl 
formation. Squamous cell carcinoma tends to be slow-growing, and it is estimated that the 
progression of in situ carcinoma to a clinically apparent tumor takes three to four years 
(Carter et al. 1985). 
1.3.5. Adeno-squamous carcinoma 
Adeno-squamous carcinomas have histological areas differentiated into both squamous cell 
carcinoma and adenocarcinoma. They are predominantly found in the periphery of the lung 
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and have clinical behavior more like that of adenocarcinoma. However, studies suggest 
that they are a cytogenetically distinct entity (Takamori et al. 1991) 
1.3.6. Pleomorphic carcinomas 
This grouping of tumors includes carcinomas with giant and usually multinucleated cells, 
those carcinomas with a spindle cell, pseudo-sarcomatous configuration, and those with 
both carcinoma and sarcoma morphology, including the rare pulmonary blastoma. All are 
aggressive malignancies and usually found at a high stage, but survival is stage-dependent 
(Ginsberg et al. 1992) 
1.3.7. Carcinomas of salivary gland type 
These carcinomas include muco-epidermoid carcinomas (low and high grade), recognized 
by their characteristic intermediate or transitional cells, adenoid-cystic carcinoma, which 
shares the aggressiveness of its salivary gland counterpart, and the low-grade, acinic cell 
carcinoma. All are predominantly found in large bronchi and thought to arise from 
submucosal gland epithelium (Yousem et al. 1987). 
 
1.4. Clinical manifestations 
The signs and symptoms of patients who suffer from lung cancer depend on the histology 
of the tumor and the extent of loco-regional invasion, as well as the location, size, and 
number of distant metastases. Many patients present with an asymptomatic lesion 
discovered incidentally on chest radiography or CT scan. 
Tumors arising in the larger airways cause persistent cough, wheezing or hemoptysis. If 
pleural surfaces are involved either by the primary tumor or associated infection, pleuritic 
pain develops with or without a pleural effusion. The loss of lung function was associated 
with dyspnea, the severity of which depends on the amount of lung involved and the 
patient's underlying pulmonary reserve. Tumors invading the chest wall typically produce 
either stabbing or burning radicular pain with or without pleural effusion.  
Tumors arising within the superior sulcus are associated with a Pancoast syndrome due to 
invasion of the lower brachial plexus (T1 and C8 nerve roots), stellate ganglion, and chest 
wall or vertebral bodies. Invasion or encasement of structures within the mediastinum 
result in superior vena cava syndrome, recurrent or phrenic nerve palsy, esophageal 
dysphagia, trachea-esophageal fistula, or pericardial effusion. 
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Nearly all patients with advanced non-small cell lung cancer exhibit symptoms referable to 
their disease on initial presentation. Fatigue and decreased activity are reported by more 
than 80% of individuals, and most patients also experience cough, dyspnea, anorexia, and 
weight loss. The presenting complaints of patients with metastatic disease are largely 
determined by the specific sites involved, such as bone, brain, liver, and adrenal glands. In 
addition, patients could exhibit a variety of paraneoplastic syndromes such as hypertrophic 
pulmonary osteoarthropathy, clubbing of the digits, etc. (Ginsberg et al. 2004). 
 
1.5. Treatment of locally advanced non–small cell lung cancer 
Non-small cell lung cancer (NSCLC) includes adenocarcinoma and its bronchioloalveolar 
subset, squamous cell carcinoma, and large cell carcinoma, in decreasing order frequency 
of occurrence. Non-small cell lung cancer (NSCLC) accounts for at least 80% of all lung 
tumors. About 35% of these patients present with locally advanced non-metastatic disease 
(Jemal et al. 2004).  
Stage III non–small cell lung cancer is defined as loco-regionally advanced disease, based 
upon mediastinal lymph node involvement or extension into extra-pulmonary structures, 
without evidence of distant metastases. The International Staging System subdivides stage 
III NSCLC into stages IIIA and IIIB. Stage IIIA is based upon the presence of ipsilateral 
mediastinal lymph node (N2) involvement or a T3 lesion with positive hilar nodes (N1). 
Stage IIIB disease is characterized by supraclavicular or contralateral mediastinal lymph 
node involvement (N3) or a T4 primary tumor (Greene et al. 2002).  
Patients with stage IIIA disease are stratified clinically into those with bulky and non-
bulky disease, based upon the presence of lymph nodes > 20mm in short-axis diameter, as 
measured by CT, or groupings of multiple smaller lymph nodes. These distinctions 
between non-bulky and bulky IIIA and IIIB disease are important for prognostic purposes, 
rather than for determining the therapeutic approach (Appendix B). 
Despite therapeutic advances over the past two decades, these patients’ prognosis remains 
poor, with a 5-year survival rate of only 10 –15%. Until the late 1980s, radiotherapy was 
the only treatment option. The Radiation Therapy Oncology Group (RTOG) had shown 
that local disease control was improved by increasing the total dose to 60Gy delivered in 
30 fractions over 6 weeks (Perez et al. 1982, Perez et al. 1986).  
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1.5.1. Induction chemotherapy and radiation 
The 1990s saw the emergence of both sequential and concurrent combinations of 
chemotherapy and radiotherapy. A number of randomized phase III trials, and several 
meta-analyses, showed that chemo-radiotherapy was superior to radiotherapy alone in 
terms of overall survival (Le Chevalier et al. 1992, Auperin et al. 2006).  
LeChevalier et al. randomly assigned 353 patients to receive either induction 
chemotherapy with lomustine, vindesine, cyclophosphamide, and cisplatin followed by 
65Gy of radiotherapy or radiotherapy alone, with 3-year survival rates of 12% versus 4%, 
respectively (P<0.02). This trial also monitored the pattern of relapse (local versus 
systemic) and found that the reduced failure and improved survival rate in chemotherapy-
treated patients was a result of improved distant disease control (Le Chevalier et al. 2000). 
The Cancer and Leukemia Group B (CALGB) conducted a seminal study (CALGB 8433) 
in which patients with inoperable stage IIIA or IIIB disease were randomly assigned to 
receive two cycles of cisplatin and vinblastine over 5 weeks followed by radiation therapy 
to 60Gy versus radiation therapy to 60Gy without chemotherapy. The response rate was 
56% for patients receiving chemotherapy and radiation compared with 43% for patients 
receiving radiation therapy alone; median survival time were 14 months versus 10 months, 
respectively (p=0.0066). More importantly, there was a 17% survival rate at 5 years in the 
combined-modality therapy arm versus a 7% rate in the radiation therapy alone arm, with 
few patients experiencing relapse after 2 to 3 years of follow-up (Dillman et al. 1996).  
Not all trials testing induction chemotherapy in stage III NSCLC have been positive 
(Morton et al. 1991). However, it has been pointed out that those trials used less aggressive 
chemotherapy and entered smaller cohorts of patients. The survival advantage with 
induction chemotherapy has been confirmed by a meta-analysis of these trials (Marino et 
al. 1995). 
1.5.2. Concurrent chemotherapy and radiation 
Concurrent therapy seemed to give better results than sequential therapy, but this needed to 
be demonstrated. In a phase III trial from the West Japan Lung Cancer Group, 320 patients 
were randomly assigned to receive thoracic radiation (56Gy, split-course) either after or 
concurrent with cisplatin (80mg/m
2
), vindesine (3mg/m
2
), and mitomycin (8mg/m
2
) 
chemotherapy. Patients receiving concurrent therapy had a median survival time of 16.6 
months compared with 13.3 months for the sequentially treated patients (p=0.03). The 5-
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year survival rate was also superior for the concurrently treated patients (15.8%) compared 
with patients receiving sequential therapy (8.9%). This was the first randomized phase III 
trial to show a statistically significant improvement in overall survival after concurrent 
chemo-radiotherapy, with no increase in esophageal toxicity (Furuse et al. 1999).  
Curran et al. report the results of the RTOG 94-10 study, which compared three schedules: 
sequential treatment with cisplatin–vinblastine induction chemotherapy followed by 
radiotherapy at a total dose of 63Gy (arm 1); a concurrent schedule in which two cycles of 
cisplatin–vinblastine were administered during the same radiotherapy schedule as in arm 1 
(arm 2); and another concurrent schedule combining cisplatin–etoposide chemotherapy 
with bi-fractionated radiotherapy at a total dose of 69.6Gy (arm 3). Arm 2 was first 
compared with the sequential schedule, which served as the reference treatment, and then 
arm 3 was compared with the better of the other two arms. The median survival time was 
superior for patients receiving concurrent daily radiation (17.0 months) compared with 
patients receiving sequential therapy (14.6 months); this result was statistically significant 
(p=0.038). The overall 4-year survival rate was also better for patients on the concurrent 
arm compared with the sequential arm (21% versus 12%, respectively) (Curran et al. 
2011).  
A similar experience has been reported by Fournel et al in the Groupe Lyon-Saint-Etienne 
d'Oncologie Thoracique – Groupe Français de Pneumo - Cancérologie study NPC 95-01. 
In this phase III trial, 212 patients received thoracic radiation (66Gy) and were randomly 
assigned to either the sequential arm with induction chemotherapy consisting of cisplatin 
(120mg/m
2
) and vinorelbine (30mg/m
2
 weekly) or to concurrent therapy consisting of 
cisplatin (20mg/m
2
) and etoposide (50mg/m
2
) for two cycles along with thoracic radiation. 
All patients received consolidation chemotherapy that consisted of cisplatin (80mg/m
2
) and 
vinorelbine (30mg/m
2
 weekly) for eight cycles. Median survival time of 14.5 months was 
observed for the sequentially treated patients compared with 16.3 months for the 
concurrent arm. It is important to note that this result did not achieve statistical 
significance (p=0.24). The 2- and 4-year survival rates in the sequential arm were 26.5% 
and 14.2%, respectively, and in the concurrent arm were 39.3% and 20.7%, respectively, 
(Fournel et al. 2005). However, the benefit persisted at 5 years, in which the improvement 
in overall survival observed with the concurrent schedule was stable at 5 years (18.5% 
versus 8.5%) and at 7 years (15% versus 5.8%) (Fournel et al. 2008). 
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In an additional European trial reported by Zatloukal et al, 102 patients were randomly 
assigned to four cycles of cisplatin (80mg/m
2
) and vinorelbine (25mg/m
2
) chemotherapy 
with radiation (60Gy) starting on either the second cycle (concurrent arm) or after the 
completion of the chemotherapy (sequential arm). The median survival time was 
significantly longer for patients receiving concurrent therapy (16.6 months) compared with 
patients receiving sequential therapy (12.9 months) (Zatloukal et al. 2004). 
1.5.3. Induction/ consolidation chemotherapy in addition to concurrent chemo-
radiotherapy 
Although it is clear that concurrent chemo-radiotherapy is superior to sequential 
chemotherapy followed by radiation or radiation alone in patients with good performance 
status and no significant weight loss, several important questions remain controversial and 
unanswered. It is not certain whether patients benefit from additional chemotherapy 
administered at systemically active doses (in the induction or consolidation phase) in 
addition to concurrent chemo-radiotherapy (Auperin et al. 2010, Blackstock et al. 2007). 
A phase III study (CALGB 39801) randomly assigned 366 patients with locally advanced 
NSCLC to two cycles of induction chemotherapy with paclitaxel (200mg/m
2
) and 
carboplatin administered every 3 weeks followed by weekly paclitaxel (50mg/m
2
) and 
carboplatin (AUC=2) with thoracic radiation or the same regimen without induction 
chemotherapy. The median survival time was a mere 12 months (95% CI, 10 to 16 months) 
without the induction regimen and only 14 months (95% CI, 11 to 16 months) with the 
induction therapy (Vokes et al. 2007). 
These results are not that different from those observed in the seminal CALGB study 
conducted two decades ago that compared radiation alone (9.6 months) with sequential 
chemotherapy followed by radiation (13.7 months) (Dillman et al. 1990). Unlike the 
previous CALGB studies, weight loss of more than 5% was not a specific exclusion 
criterion in this study. In the subset of patients with weight loss of more than 5% (n=87), 
induction therapy followed by concurrent chemo-radiotherapy resulted in a better overall 
3-year survival rate than concurrent chemo-radiotherapy alone (23% versus 10%, 
respectively). 
In Southwest Oncology Group (SWOG) study 9504, 83 patients with stage IIIB disease 
were treated with cisplatin-etoposide, and concurrent radiotherapy followed by three cycles 
of docetaxel; this regimen resulted in an impressive median survival time of 26 months and 
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a 3-year survival rate of 37% (Gandara et al. 2003). These results compared favorably with 
their previous study (SWOG 9019) in the same population when patients were treated with 
cisplatin-etoposide, and concurrent radiation followed by two additional cycles of cisplatin 
and etoposide. In this study, the median survival time was 15 months, and the 3-year 
survival rate was 17% (Albain et al. 2002). Although the SWOG 9504 results are 
encouraging after a series of disappointing results, the unprecedented results raised 
questions regarding patient selection given the known heterogeneity of the locally 
advanced NSCLC subset. 
Several other randomized phase II and III trials have compared induction chemotherapy 
followed by concurrent chemo-radiotherapy versus concurrent chemo-radiotherapy 
followed by consolidation chemotherapy. Neither strategy proved superior to chemo-
radiotherapy alone. However, several lines of evidence support early chemo-radiotherapy 
(Akerley et al. 2005, Belani et al. 2005, Vokes et al. 2007, Hanna et al. 2008). 
The Hoosier Oncology Group (HOG) conducted a phase III study involving 203 patients 
with locally advanced NSCLC who received cisplatin, etoposide, and thoracic radiation; 
patients without disease progression were then randomly assigned to observation or three 
cycles of docetaxel administered every 3 weeks. Of 203 patients enrolled, 147 (72%) were 
randomly assigned to consolidation docetaxel (n=73) or observation (n=74). The addition 
of docetaxel did not improve progression-free survival or overall survival in this study. 
Consolidation docetaxel resulted in increased rates of infections, pneumonitis, and 
treatment-related death when compared with observation alone. The overall survival time 
for the entire study population was 21 months (95% CI, 17.1 to 25.3 months), and the 3-
year survival rate was 28%, which is better than any multi-institutional randomized study 
reported so far in this population (Hanna et al. 2008). 
Two recent Japanese trials (Yamamoto et al. 2010, Segawa et al. 2010) showed no 
superiority of chemotherapy regimens including third-generation drugs compared with 
older protocols. Concurrent chemo-radiotherapy gave median overall survival time often 
exceeding 20 months and 2-year survival rates of between 40% and 60%. Surprisingly, 
these favorable results were obtained with the same chemotherapy regimen as that used in 
the trial published by Furuse et al (Furuse et al. 1999).  
Currently, technological advances in thoracic radiotherapy, including four-dimensional 
dosimetry and intensity-modulated radiation therapy, may contribute to improvement of 
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results (Liao et al. 2010). Indeed, conformal radiotherapy reduces toxicity for healthy 
bystander tissues and, in some patients, allows the dose to be increased, up to 74Gy 
(Bradley et al. 2010).  
 
1.6. Purpose of the study 
Vietnam is located on the eastern Indochina Peninsula. It covers a total area of 
approximately 331,210 km
2
, making it almost the size of Germany (357,021 km
2
). The 
census in 2009 recorded population of Vietnam as standing at approximately 85.8 million, 
ranking 13
th
 in globally. According to the National Registry of Cancer, Vietnam had 
150,000 new cases of cancer each year (Pham et al. 2002). The leading cancers in this 
country were lung, liver, stomach, colorectum and nasopharynx in males and breast, 
cervix, stomach, liver, colon–rectum and lung in females. The data of cancer statistics in 
Vietnam are shown in Table 1.1 (Ferlay et al. 2010). 
Table 1.1. Cancer statistics of Vietnam (Ferlay et al. 2010) 
Types of cancer Morbidity (n, %) Mortality (n, %) 
Liver 23,251 (20.8) 21,748 (26.5) 
Lung 20,659 (18.5) 17,583 (21.4) 
Stomach 15,068 (13.5) 11,327 (13.8) 
Colorectal 7,367 (6.6) 4,131 (5) 
Breast 6,830 (6.1) 2,423 (3) 
Cervix 5,174 (4.6) 2,472 (3) 
Hematology 4,355 (3.9) 3,594 (4.4) 
Nasopharynx 3,537 (3.2) 2,688 (3.3) 
Central nervous system 3,220 (2.9) 2,646 (3.2) 
Others  22,120 (19.8) 13,394 (16.3) 
There was a shortage in cancer hospitals in this country, especially radiotherapy (RT) 
facilities and these facilities were located in the major cities such as Hanoi and Ho Chi 
Minh City. The available RT equipment in Vietnam were included 10 Brachytherapy units, 
7 Simulators, 14 Co-60 Teletherapy units, 8 Linear Accelerators, 3 Gamma-Knifes and 1 
Cyber-Knife. This is well below from the IAEA recommendation of at least one machine 
per million populations (Le TA 2008). 
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Cho Ray hospital was a government teaching hospital that belongs to Ministry of Health. It 
was located in Ho Chi Minh City and was also the top referral hospital for more than 30 
provincial hospitals in South Vietnam. Cho Ray had more than 40 clinical wards, surgical 
departments for almost every kind of cancer. It had comprehensive diagnostic imaging 
(Ultrasound, CT scan, MRI, and DSA) and nuclear medicine (SPECT, PET – CT) 
facilities. The Department of Oncology, which was established in 2002, had 6 radiation 
oncologists, 4 medical oncologists, 6 medical physicists, 16 radiation therapists and 7 
nurses. This department was well-equipped with two Linear Accelerators, one Simulator, 
two Treatment Planning Systems (DSS and Leibinger). The available radiotherapy 
techniques included 2D radiotherapy, 3D-CRT and radiosurgery.  
In Vietnam, many lung cancer patients came to hospital in very advanced stages, therefore, 
their survival were quite poor. As stated previously, the optimal treatment for locally 
advanced NSCLC continued to involve, but combined-modality therapy has led to improve 
survival rates versus treatment with radiation alone or sequential chemo-radiotherapy, and 
was the standard of care. However, due to the shortage in radiotherapy equipment, many 
stage III NSCLC patients in this country were being treated with palliative intent by 
chemotherapy alone or supportive care only. This was the main reason why we would like 
to set up a study to treat the patients with stage III NSCLC by concomitant chemo-
radiotherapy with the following objectives: 
1- Primary objective: 
- Determine the efficacy of combining radiotherapy and chemotherapy concurrently in 
treatment of the patient with stage III NSCLC by analyzing the median survival time in the 
study population. 
2- Secondary objectives: 
- Determine the efficacy of combining radiotherapy and chemotherapy concurrently in 
treatment of the patient with stage III NSCLC by analyzing the progression-free survival, 
the overall survival and the response rate. 
- Assess the safety and tolerability of patients receiving concomitant chemo-radiotherapy. 
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2. PATIENTS AND METHODS 
 
2.1. Patients 
Non-small cell lung cancer (NSCLC) includes adenocarcinoma and its bronchioloalveolar 
subset, squamous cell carcinoma, and large cell carcinoma, in decreasing order frequency 
of occurrence. Stage III non-small cell lung cancer is defined as loco-regionally advanced 
disease, based upon mediastinal lymph node involvement or extension into extra-
pulmonary structures, without evidence of distant metastases (Greene et al. 2002). 
All patients who presented to the Department of Oncology, Cho Ray hospital, Ho Chi 
Minh City, Vietnam with lung cancer over a three year period from March 1
st
, 2009 to 
March 1
st
, 2012 were recorded in a prospective database. Patients with stage III NSCLC 
who satisfied the following inclusion criteria were accrued into this prospective study. The 
study cohort was selected from all patients with locally advanced NSCLC who presented 
to the Department of Oncology during this period. The study protocol was approved by the 
Institutional Review Board of Cho Ray hospital. 
2.1.1. Inclusion criteria 
Patient must satisfy all the following entry criteria before participating in the study: 
1. Age greater than 18 years 
2. Histologically proven non-small cell lung cancer (NSCLC) including squamous 
cell carcinoma, adenocarcinoma, bronchioloalveolar carcinoma, large cell 
carcinoma. 
3. Untreated locally advanced stage IIIA or stage IIIB: no prior systemic 
chemotherapy, thoracic radiotherapy or complete surgical resection.  
4. Karnofsky Performance Status ≥ 80% (Appendix D) 
5. Patients without weight loss > 10% within the previous 3 months before diagnosis 
6. Adequate bone marrow, hepatic and renal functions: 
– Granulocyte count > 2.0 x 109/l 
– Platelet count > 100 x 109/l 
– Hemoglobin > 10 g/dl 
– Total Bilirubin < 1.5 x ULN 
– Transaminases < 2.5 x ULN 
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– Creatinine < 1.5 x ULN 
– Forced expiratory volume in 1 second (FEV1) > 800mL 
7. Patients were required to have at least one measurable lesion according to 
RECIST criteria (Appendix E) 
8.  Patients were able to comply with the treatment protocol and follow-up. 
9.  Signed written consent form. 
2.1.2. Exclusion criteria 
Patient should not enter the study if any of the following applied: 
1. NSCLC stage I, II and IV. 
2. NSCLC stage IIIB with malignant pleural effusion. 
3. Concomitant/ uncontrolled medical disorder (cardiac failure or myocardial 
infarction within the previous three months; uncontrolled hypertension or 
arrhythmia) 
4. Weight loss > 10% within the previous three months 
5. Pre-existing malignant pleural effusion  
6. Ascites or pericardial effusion 
7. Active secondary malignancy except appropriately treated carcinoma in situ of 
the cervix or skin basal cell cancer.  
8. Known hypersensitivity to the study drugs or to drugs with similar chemical 
structures 
9. Women if pregnant or breast-feeding or with positive pregnancy test at inclusion 
 
2.2. Diagnosis  
Two weeks before study entry, the patients who satisfied all selection criteria and not 
committed to exclusion criteria were undertaken a complete medical history and a physical 
examination, together with preliminary investigations. These included: weight, 
performance status, white blood counts/ granulocytes, hemoglobin, platelet count, SGOT, 
SGPT, total bilirubin, albumin, glucose and creatinine. Pulmonary function tests and an 
ECG were also performed on patients before study entry. Radiographic assessments, 
including CT scans and bone scans, were obtained to document tumor staging for 
eligibility. CT scans were used consistently for all evaluations and tumor measurements 
during the entire study period. 
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2.3. Treatment  
2.3.1. Rationale of treatment 
Combined chemo-radiation therapy was currently considered a standard of care for patients 
with stage IIIA or IIIB NSCLC who were not candidates for surgical resection. 
Concomitant chemo-radiotherapy offered an alternative strategy for combined therapy 
because it could provide both local and distant control simultaneously. Various agents have 
been used either sequentially or concurrently in many trials of combined chemo-
radiotherapy for NSCLC. Clinically, however, no chemotherapy combination has proven 
superiority in a combined-modality setting (Vokes et al. 2005).  
The analysis of many prospectively randomized trials in stage III NSCLC revealed a 
significant increase in treatment–related toxicities within concurrent chemo-radiation 
protocols, especially with second generation chemotherapy (Curran et al. 2011, Furuse et 
al. 1999, Fournel et al. 2005). 
The benefit of the introduction of third-generation has begun to be assessed in terms of less 
treatment-related adverse events (Belani et al. 1997, Choy et al. 2000, Vokes et al. 2002). 
The ECOG study that compared four commonly used regimens (cisplatin/paclitaxel, 
cisplatin/docetaxel, cisplatin/gemcitabine and carboplatin/paclitaxel) for front-line therapy 
of advanced NSCLC demonstrated similar efficacy including response rate, median 
survival and 1-year survival for all four regimens. Therefore, carboplatin/paclitaxel was 
chosen as the reference regimen for other ECOG trials based on its favorable therapeutic 
index (Schiller et al. 2002). The results of a Southwest Oncology Group study also 
demonstrated a favorable tolerability profile for the carboplatin/paclitaxel regimen 
compared with cisplatin/vinorelbine (Kelly et al. 2001).  
Radiosensitizer properties of paclitaxel have been shown both in vitro and in animal 
models (Mote et al. 1996, Leonard et al. 1996). Efforts to improve the tolerability profile 
of this regimen have focused on administration of lower doses of paclitaxel (175 to 
200mg/m
2
) or by administering paclitaxel on a weekly schedule (Kosmidis et al. 2000). 
Weekly schedules were preferred as a compromise between possible radiosensitization and 
feasibility. In Vietnam, the regimen of carboplatin and paclitaxel was still the most 
commonly used regimen for the treatment of advanced NSCLC. Therefore, this 
combination at reduced dose was chosen to combine concurrently with radiotherapy for 
locally advanced non-small cell lung cancer at Cho Ray. 
17 
 
2.3.2. Chemotherapy administration 
Following entry into the study, patients were planned to receive weekly paclitaxel with 
carboplatin for six consecutive weeks. The paclitaxel was administered at 45mg/m
2
 
intravenously (in one hour) and the carboplatin being given at a formula time versus 
concentration curve (AUC) of two intravenously (in 30 minutes) following administration 
of paclitaxel.  
Surface area was calculated using actual patient’s height and weight. The dose of 
carboplatin was calculated at 25 plus creatinine clearance x the desired AUC, according to 
the Calvert formula. In which, creatinine clearance was determined as 140 – patient age x 
weight in kilograms ÷ by 72 x serum creatinine x (0.85 for female patients) (Calvert et al. 
1995).  
Thirty minutes before paclitaxel, patients received intravenous premedication consisting of 
Dexamethasone 8 mg, Promethazine 50mg, and Ranitidine 50mg or other drugs of the 
same classes in comparable doses. Patients could receive anti-emetics, if required, but no 
cytotoxic, hormone, or immunotherapy and no regular supportive treatment with 
granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating 
factor. 
Figure 2.1.Schema of patient selection for the study 
 
 
 
 
 
 
 
 
      Regimen of concurrent chemo-radiotherapy 
      Paclitaxel - Carboplatin/ weekly for 6 consecutive doses 
 
 
            Radiotherapy 60Gy/ 30 fractions 
 
1158 lung cancer patients admitted to 
Cho Ray hospital from 3/09-3/12 
423 patients with locally 
advanced NSCLC 
60 patients satisfied 
the selection criteria 
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Chemotherapy dose modifications 
1. Platelet count of 50,000 to 74,999/mm3 or granulocyte count of 1,000 to 1,499/mm3 
on the day of planned treatment, 50% of carboplatin and paclitaxel were 
administered.  
2. Platelet count of less than 50,000/mm3 and for a granulocyte count of less than 
1,000/mm
3
, chemotherapy was withheld.  
3. For esophagitis, mucositis, stomatitis and dermatitis of grade 3, during 
radiotherapy, paclitaxel was delayed one week and carboplatin was continued. 
Paclitaxel was resumed once toxicity had resolved to grade 2.  
4. For grade 4 toxicities, all protocol therapy was held and resumed at a 50% dose 
following resolution of toxicity to grade 2.  
 
2.3.3. Radiation therapy 
Radiotherapy was administered concurrently with 6 cycles of chemotherapy, starting on 
day 1 of the first cycle of chemotherapy. A total dose of 60Gy was administered at five 
fractions per week for 6 consecutive weeks at fractionation of 2Gy.  
2.3.2.1. Radiotherapy planning and delivery  
Data acquisition for radiotherapy was performed on a Siemens Somatom® Sensation 4 CT 
scanner (Siemens AG) fitted with a flat tabletop and laser localization. Patients were 
immobilized in the supine position and arms resting over the head to allow for lateral 
fields. Immobilization device for patient’s body included a lungboard (Medtec). CT scan 
images (after injection of contrast medium) were acquired in the treatment position before 
planning and simulation. CT acquisition covered the whole treated volume, including 
tumor, nodes, spinal cord, lungs and heart, i.e. usually from larynx to L2. The slices were 
contiguous and 5mm in thickness. 
Radiotherapy planning was performed on DSS® (Decision Support System) Multidata 
computerized 3-D treatment planning system (Multidata System International 
Corporation). Blocks were designed according to computer dosimetry, i.e. taking into 
account the physical penumbra around the PTV. A Siemens Symview® treatment 
simulator (Siemens AG) was used for verification simulation. Simulation films were also 
taken to further assess setup and field arrangements. Radiotherapy was delivered on a 
Siemens Primus® linear accelerator (Siemens AG) with 6MV photon energies. Treatments 
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usually consisted of three to four fields at 3-4 gantry angles. Portal images of treated 
beams with blocks were taken on the first day of treatment to verify setup and plan. 
Figure 2.2. Data acquisition with Siemens Somatom® Sensation 4 CT scanner 
 
 
Figure 2.3. Radiotherapy on Siemens Primus® linear accelerator 
 
 
2.3.2.2. Definitions of target volumes 
Gross Tumor Volume (GTV) 
GTV was the gross demonstrable extent and location of the malignant growth (primary 
tumor and involved lymph nodes). The determination of the GTV was based on clinical, 
endoscopic and CT scan. The extension of the primary tumor was determined using the CT 
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lung windows. Lymph nodes were defined as involved if larger than 15mm, if they showed 
central hypodensity or if multiple lymph nodes larger than 10mm were seen in the same 
compartment. Lymph nodes were defined using CT mediastinal soft tissue windows. 
Clinical target volume (CTV)  
CTV involved adding a margin for suspected micro extension around the primary GTV. 
Standard margin of 5mm was set around the GTV primary involved lymph nodes. 
Planning Target Volume (PTV) 
PTV was designed to treat the primary tumor and macroscopically involved lymph node 
compartments. The PTV adds margins to the GTV and considers both oncological 
subclinical extension and geometrical (setup and motion uncertainty) factors. A lateral 
margin of 10mm and a 15mm margin in the cranio-caudal direction (as breathing mobility 
is higher in z direction) are added to the GTV.  
Dose was specified according to ICRU 50. Dose was calculated at the ICRU reference 
point preferentially at the intersection of the treatment beams in the isocenter plane. The 
surface of the PTV was covered by the 95% isodose. The maximum dose was located in 
the target volume and should not exceed 110% isodose. Normalization could use the 
median dose in the PTV. Single doses of 2Gy/fraction were given each day, five days a 
week to total dose of 60Gy. All fields were treated daily. Breaks were avoided if possible. 
2.3.2.3. Critical organs 
Critical organs were defined as the lungs and spinal cord. The doses delivered to these 
organs was calculated and displayed on dose-volume histograms. The recommended 
radiotherapy planning dose constraints were defined as: 
• Lung: The volume of lung receiving greater than 20Gy (V20) should be kept less than 
35% of the total volume of both lungs minus the PTV: V20 < 35% lung volume. 
• Spinal cord: The maximum dose to the spinal cord should be less than 45Gy. Dmax < 
45Gy. 
 
2.3.2.4. Irradiation techniques 
A CT-based 3-D treatment technique was designed to treat an individually shaped target 
volume and minimize dose to critical organs at risk (spinal cord, lung). An isocentric 
technique using multiple fields and shaped beams with satellite blocks was recommended. 
Sparing of the contralateral lung was considered paramount. Ideally, the total lung volume 
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(excluding the PTV) that received more than 20Gy should be less than 35% (dose volume 
histogram analysis). The dose to the spinal cord should not exceed 45Gy at a single dose of 
2Gy. Anterior-posterior/ posterior-anterior fields with spinal cord shielding were not 
recommended as it resulted often in reduced doses to the target volume. Documentation of 
the treatment techniques at the simulator and representative port verification at the 
treatment machine at first day of radiotherapy were mandatory. 
2.3.2.5. Modifications of radiotherapy 
1. Hematological toxicities: in case of febrile neutropenia associated or not with 
platelets < 10.000/mm
3
, the radiotherapy should be delayed until the patient has 
recovered with apyrexia. 
2. Esophagitis grade 3: chemotherapy should be delayed for one week. Radiotherapy 
should be continued, if possible. If the patients had not recovered after two weeks, 
the patient would be withdrawn from the study. Treatment should be discontinued 
in case of grade 4 esophagitis. 
 
2.4. Methods 
All patients who presented to the Department of Oncology with lung cancer from March 
1
st
, 2009 to March 1
st
, 2012 were recorded in a prospective database. The patients had 
pathological diagnosis by endoscopic biopsy, lymph nodes biopsy or post-surgery. All 
patients underwent staging with clinical examination, bronchial endoscopy, abdomen 
ultrasound, CT scan of the brain, chest and abdomen with or without contrast, and bone 
scan. 
2.4.1. Data survey and documentation 
Patients were informed on their diagnosis, prognosis and treatment alternatives. Clinical 
details were recorded prospectively and included name, gender, age, personal and family 
histories, social habits like smoking, histology, clinical presentation, performance status, 
weight loss in previous three months, details of treatment regimen, toxicities and outcome 
of treatment. 
2.4.2. Evaluation of responses 
All eligible patients were considered as assessable for responses and toxicities. Cell blood 
count, transaminases, blood urea nitrogen (BUN), serum creatinine were repeated once a 
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week during the treatment period. In order to record response rates, patients underwent a 
repeated CT scan at 8-12 weeks following the ending of treatment. The results of this scan 
were compared with baseline CT scan and responses were evaluated in accordance with 
Response Evaluation Criteria in Solid Tumors (RECIST version 1.0) (Appendix E).   
For the follow up after the treatment, repeated CT scans were obtained every three months 
in the first year and every six months in the following years or when recurrences were 
suspected. All survival time were defined as the time from start of treatment to progression 
or last follow-up (progression-free survival) or death of any cause (overall survival). 
2.4.3. Endpoints of study 
The primary endpoint was the median survival time analyzed in the study population. 
The secondary endpoints were:  
 Progression-free survival, 
 Overall survival, 
 Response rates, 
A multivariate analysis using a Cox proportional hazard model for time to progression and 
time to death/ last follow-up was performed taking into account the following prognostic 
factors: 
 Stages (IIIA/ IIIB), 
 Histological subtypes (Adenocarcinoma/ Squamous cell carcinoma/ 
Bronchioloalveolar carcinoma), 
 Age groups (under 60 years old/ from 60 – 69 years old/ over 69 years old), 
 Pretreated weight loss status (under 5% or from 5-10% of their normal weights). 
90/ KPS 80). 
 
2.4.4. Toxicity assessment 
The National Cancer Institute Common Toxicity Criteria (NCI-CTC) classification version 
2.0 was used to classify all adverse events and toxicities (Appendix C). All observed 
toxicities were recorded after each cycle. Hematologic parameters were observed weekly. 
Blood chemistry parameters and clinical examination results were also obtained before 
every cycle of chemotherapy and after the end of therapy.  
Hematological parameters were consisted of white blood count, granulocytes, platelets and 
hemoglobin. Biochemical parameters included serum glutamic oxaloacetic transaminase 
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(SGOT), serum glutamic pyruvic transaminase (SGPT), and serum creatinine. In addition, 
non-hematological toxicities such as nausea/ vomiting, alopecia, dermatitis, fatigue/ 
anorexia, weight loss, infection, odynophagia/ dysphagia and cough/ dyspnea should be 
assessed by clinical exam.  
Maximum NCI-CTC grades or severity were reported by cycle and by patient. In order to 
examine the evolution of biochemical toxicities, worst NCI-CTC grade would be analyzed 
in relation to the grade presented at baseline. 
 
2.5. Statistics 
This trial was a single institution, prospective, single-arm study. The statistical analysis 
was performed using STATA 11.0 software package (Statacorp®). Continuous data was 
summarized with the following parameters: frequency, median (if n ≥ 3), range and mean 
and standard deviation of the mean if relevant. Categorical data was presented in 
contingency tables with frequencies and percentages of each modalities (including missing 
data modality). To describe time dependent parameters, Kaplan-Meier curves and life 
tables by subgroups were provided. Log-rank test were performed to compare the 
subgroups for progression-free survival and overall survival. P< 0.05 was considered 
statistically significant. Multivariate analyses were performed to take into account the 
prognostic factors. A Cox proportional hazard model would be applied to the data.  
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3. RESULTS 
 
3.1. Characteristics of lung cancer patients at Cho Ray hospital 
All patients who presented to the Department of Oncology, Cho Ray hospital, Ho Chi 
Minh city, Vietnam with lung cancer from March 1
st
, 2009 to March 1
st
, 2012 were 
recorded in a prospective database. The patients had previous pathological diagnosis by 
endoscopic biopsy, lymph nodes biopsy or post-surgery. All patients were recorded their 
ages, genders, races, primary referral hospitals, clinical symptoms at presentation, subtypes 
of histology, stage of disease and treatment options.  
There were 1,158 patients diagnosed with lung cancer and treated at Department of 
Oncology, Cho Ray hospital. The number of male patients decreased slightly in the year of 
2010 but the number of female patients were almost unchanged in three consecutive years 
(Figure 3.1). 
Figure 3.1. Amount of lung cancer patients in three years  
 
3.1.1. Patient demographics 
Age and gender:  
All patients were Vietnamese, including 821 men (70.9%) and 337 women (29.1%). Thus, 
the ratio of male to female patients was approximately 7: 3. As shown in Figure 3.2, the 
age distributions of male and female patients were quite similar, although women in 
general were slightly younger than men at the time of diagnosis.  
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Percentage (%) 
In men, 9.9% of lung cancer cases were diagnosed among people aged 0 to 44 years, 
30.3% in the 45 to 54 age group, 33.6% in the 55 to 64 age group, and 26.2% among those 
aged 65 years and over. In females, 17.5% of lung cancer cases were diagnosed among 
people aged 0 to 44 years, 31.8% in the 45 to 54 age group, 30% in the 55 to 64 age group, 
and 20.8% among those aged 65 years and over. The median age was 56 years old (with 
the range from 20 to 87 years of age). The median ages at the time of diagnosis in male 
and female were 57 (range from 26 to 87) and 55 (range from 20 to 86), respectively. 
Figure 3.2. Age distribution of patients at the time of diagnosis 
 
 
Geographic referral patterns 
Cho Ray hospital is located at Ho Chi Minh city. It is also the main referral hospital for the 
South of Vietnam, that has a population of 40 million. Patients admitted to Cho Ray with 
lung cancers came from almost all provinces in the South Vietnam. Many patients lived at 
Ho Chi Minh city (29.1%) and in nearby regions such as Dong Nai Province (5.7%), Long 
An Province (4.4%), Binh Duong Province (4%) and Tien Giang Province (3.5%). A small 
percentage of patients (ranging from 1.3% to 3.6%) came from the Provinces of Bac Lieu, 
Kien Giang, Daklak, Khanh Hoa and Phu Yen which are 400-700 km from Ho Chi Minh 
city (Figure 3.3). 
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Figure 3.3. Geographic referral patterns (Map of South of Vietnam) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Patient baseline characteristics 
Characteristics Number of patients Percentage (%) 
Amount of patients 1,158 100 
Gender 
     Male/ Female 
 
821/ 337 
 
70.9/ 29.1 
Histology 
     Adenocarcinoma   
     Squamous cell carcinoma 
     Small cell carcinoma 
     Large cell carcinoma  
     Others 
TNM staging 
     Stage I 
     Stage II 
     Stage III 
     Stage IV  
 
745 
131 
57 
9 
216  
 
26 
101 
449 
582 
 
64.3 
11.3 
4.9 
0.8 
18.7 
 
2.2 
8.7 
38.8 
50.3 
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3.1.2. Pathological and staging characteristics 
The patients, suspected of having lung cancer, were initially seen in the Department of 
Chest Surgery or Department of Respiratory Medicine for definitive histological diagnosis. 
They were then referred to the Department of Oncology for further consultation and 
treatment. Therefore, all patients in this series were confirmed lung cancer by histology or 
cytology. 
As shown in Table 3.1, adenocarcinomas were the most common subtype of pathology 
with 745 patients (64.3%). Squamous cell carcinomas were less common with 131 patients 
(11.3%). Small cell lung cancer (SCLC) was infrequently with percentage of 4.9%. Large 
cell carcinomas represented only 0.8% of the group. The remainder (216 patients - 18.7%) 
was not specified. This group included mainly cases where the sample was inadequate for 
classification, but allowed the diagnosis of a malignant tumor. 
Figure 3.4. Common metastatic sites  
 
 
All patients underwent staging with clinical examination, bronchial endoscopy, chest CT 
scan with or without contrast and abdomen ultrasound. CT scan of brain and/or bone scan 
were done when clinical symptoms were suspected. The majority of non-small cell lung 
cancer (986 cases, 89.5%) were diagnosed when their disease were at locally advanced 
(38.4%) or metastatic (51.1%) stages. Only 115 patients (10.5%) were diagnosed at earlier 
stages, which were potentially curable with surgery, including 24 patients (2.2%) at stage I 
and 91 patients (8.3%) at stage II. In patients with small cell lung cancer (SCLC), only 
twelve patients (21%) admitted to hospital with limited stages and forty-five patients 
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(79%) were diagnosed at extensive poor prognostic disease. As shown in Figure 3.4, forty 
per cent (233 patients) had neurologic symptoms as first clinical presentation to Cho Ray. 
Consequently, the brain was the most common site of metastases in both non-small cell 
lung cancers (39.1%) and small cell lung cancers (68.4%). Other common sites of 
metastases in patients with non-small cell lung cancers were liver (22.5%), lung and pleura 
(19.7%) and bones of multiple sites (7.3%). Other common sites of metastases in patients 
with small cell lung cancers were lung and pleural metastases (21.1%), bone (10.5%). 
There was no case of liver metastasis was recorded. 
3.1.3. Treatment modalities 
Figure 3.5. Treatment modalities 
 
As shown in Figure 3.5, 219 patients of non-small cell lung cancer (19.9%) had surgery of 
any kind, ranging from tumor biopsy via thoracotomy, lobectomy to pneumonectomy. 238 
patients (21.6%) were irradiated alone or combined with surgery or chemotherapy. The 
intent of radiotherapy in this group included curative intent to high total dose of 50 – 
60Gy. Radiotherapy with palliative intent was delivered to control local symptoms due to 
bronchial obstruction, hemoptysis, SVC obstruction and chest invasion and/or metastatic 
disease resulting in brain edema, bony pain and spinal cord compression. 715 patients 
(64.9%) received chemotherapy alone or in combined setting such as concurrent chemo-
radiotherapy or as post-operative adjuvant treatment. In patients with small cell lung 
cancer, chemotherapy was main treatment option in 40 patients (70.2%). Only 14 patients 
(24.6%) were underwent resection surgery and 7 patients (12.3%) were irradiated with 
curative intent. 
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3.2. Characteristics of patients with stage III non-small cell lung cancer 
The study cohort was selected from all patients with locally advanced NSCLC who 
presented to the Department of Oncology, Cho Ray hospital, Ho Chi Minh city, Vietnam. 
Among 423 patients diagnosed of locally advanced NSCLC, there were only 60 patients 
(14.2%) that satisfied the inclusion criteria and not committed to exclusion criteria to join 
the study. Following selection, all patients received weekly paclitaxel at 45 mg/m
2
 
intravenously (one hour) with carboplatin administered at a formula time versus 
concentration curve (AUC) of two intravenously (30 minutes) following administration of 
paclitaxel. Concurrent radiotherapy to 60Gy was administered at five fractions per week 
for six consecutive weeks at 2Gy/fraction. According to the treatment plan, radiotherapy 
was administered concurrently with six cycles of chemotherapy, starting on day 1 of the 
first cycle of chemotherapy. 
3.2.1. Patient demographics 
Table 3.2. Age, gender and subtypes of pathology 
Subtypes of 
pathology 
Males Females Total 
No. of 
patients 
Mean age 
(years old) 
No. of 
patients 
Mean age 
(years old) 
No. of 
patients 
Mean age 
(years old) 
SCCs 6 62.8 0 0 6 62.8 
ADCs 30 57.6 15 54.8 45 56.7 
BACs 6 61.7 3 59 9 60.8 
Total 42 58.9 18 55.5 60 58 
 
Out of sixty patients, there were a total of 42 men (70%) and 18 women (30%). The ratio 
of male/female patients was 2.33/1. The mean age of patients was 58 years old with the 
range from 40 to 79 years old. 60% of patients were younger than 60 and 15% aged greater 
than 69 years old. In general, female patients were younger than male patients. Mean age 
of male and female patients was 58.9 years old (ranging from 40 – 79) and 55.5 years old 
(ranging from 43 – 78) in respectively. 
Forty-five patients (75%) were classified as adenocarcinoma (ADC), nine patients (15%) 
as bronchioloalveolar carcinoma (BAC) and the remainder (10%) as squamous cell 
carcinoma (SCC). Male patients occupied 100% in SCC group and two thirds in patients 
with ADCs and BACs. The female patients occupied one third in ADCs and BACs and no 
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female patient was seen in group of SCCs. The patients with ADCs were the youngest 
(with mean age of 56.7 years old) and the SCCs were the oldest (with mean age of 62.8 
years old). Patients with BACs had mean age of 60.8 years old. Male patients with SCCs 
were oldest (62.8 years old) while female patients with ADCs were youngest (54.8 years 
old). 
Smoking history: Among sixty patients, there were only twenty-two (36.7%) of non-
smokers. 94.4% of women didn’t smoke in the past history while 88% of men were former 
or current smokers. The mean pack-years among all smokers were 29.8 (ranging from 1 to 
120 pack-years). All male patients with squamous cell carcinoma were smokers. The 
percentage of male smokers in adenocarcinoma and bronchioloalveolar carcinoma was 
86.7% and 83.3%, respectively. There was only one female smoker with histological 
diagnosis of adenocarcinoma. 
3.2.2. Clinical manifestations 
Table 3.3. Symptoms of patients at admission 
Symptoms 
SCC 
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total 
n=60 (100%) 
Cough 6 (100) 26 (65) 8 (88.9) 40 (72.7) 
Hemoptysis 3 (50) 11 (27.5) 1 (11.1) 15 (27.3) 
Chest pain 5 (83.3) 25 (64.1) 6 (66.7) 36 (66.7) 
Dyspnea 1 (16.7) 12 (30.8) 1 (11.1) 14 (25.9) 
Fatigue 0 (0) 5 (12.5) 1 (11.1) 6 (11.1) 
Hoarseness  1 (20) 2 (5) 2 (22.2) 5 (9.3) 
Dysphagia 0 (0) 3 (7.5) 0 (0) 3 (5.6) 
 
Cough (72.7%) and chest pain (66.7%) were two most common symptoms in patients of 
NSCLC. Squamous cell carcinoma patients usually presented with obstructive and local 
invasive symptoms such as cough (100%), chest pain (83.3%) and hemoptysis (50%). 
Patients with adenocarcinomas not only presented with local symptoms such as cough 
(65%) and chest pain (64.1%) but also complained of systemic symptoms such as dyspnea 
(30.8%) and fatigue (12.5%). Bronchioloalveolar carcinoma patients had similar 
presentations as patients with adenocarcinomas in both local and systemic symptoms. 
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Hoarseness due to invasion to recurrent laryngeal nerve in left main bronchus occurred in 5 
patients (9.3%) in all three types of non-small cell lung cancer. 
Performance status of patients at the time of diagnosis 
Figure 3.6. Performance status of patients at the time of diagnosis 
 
Karnofsky performance status scale (KPS) was utilized to evaluate the general status of all 
patients at the time of admission. 71.6% of patients presented with KPS scores from 90 to 
100. There were eight men and six women with a KPS score of 100. Twenty-nine patients 
(48.3%) with a KPS score of 90 (including twenty-one men and eight women). Seventeen 
patients (28.3%) had KPS score of 80 (including thirteen men and four women).  
In general, female patients had a better performance status than male patients. The ratio of 
KPS scores of 100/90/80 in male patients were 0.6/1.6/1 and in female patients were 
1.5/2/1 in respectively. As shown in Figure 3.8, no patient with SCC had KPS score of 
100, five patients had KPS score of 90 (83.3%) and one patient had KPS score of 80 
(16.7%). In patients with ADCs, 66.7% had KPS score ranging from 90-100, including 12 
patients with KPS 100 (26.7%) and 18 patients with KPS score of 90 (40%). 33.3% had 
KPS score of 80. In patients with BACs, eight patients (88.9%) had KPS score ranging 
from 90-100, including two patients (22.2%) with KPS score of 100 and six patients 
(66.7%) with KPS score of 90. Only one patient (11.1%) had KPS score of 80. 
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Weight loss status at the time of diagnosis 
Table 3.4.Weight loss status at the time of diagnosis  
Weight loss 
status 
Gender 
SCC 
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total 
n=60 (100%) 
Weight loss 
<5% 
Male 4 (66.6) 17 (37.8) 3 (33.3) 24 (40) 
Female 0 (0) 13 (28.9) 3 (33.3) 16 (26.7) 
Total 4 (66.7) 30 (66.7) 6 (66.7) 40 (66.7) 
Weight loss         
5-10% 
Male 2 (33.3) 13 (28.9) 3 (33.3) 18 (30) 
Female 0 (0) 2 (4.4) 0 (0) 2 (3.3) 
Total 2 (33.3) 15 (33.3) 3 (33.3) 20 (33.3) 
 
Forty patients (66.7%), including 24 male patients and 16 female patients, had no weight 
loss or weight loss under 5% of their normal weight in previous 3 months. Twenty patients 
(33.3%), including 18 male and 2 female patients, lost weight ranging from 5 to 10% of 
their normal weight at the time of diagnosis (Table 3.4). 57.1% of male patients had their 
weight loss under 5% while in female patients, this rate was 88.9%. In all three groups of 
pathology, one third of patients lost weight ranging from 5 to 10% and remaining two 
thirds of patients had no weight loss or loss under 5% of their normal weight. 
 
3.2.3. Staging characteristics 
3.2.3.1. Primary tumors (T) 
There were 36 lung cancer patients (60%) who had a right-sided tumor. Twenty-four 
patients (40%) had tumors on the left side. Thus, the ratio of right-sided to left-sided 
tumors was 1.5/1. Twenty-six patients (43.4%) had tumors in upper lobes of the lung. 
Fifteen patients (25%) had tumors in lower lobes. Seventeen patients (28.3%) had tumors 
in main bronchi. Only two patients had tumors in middle lobes (Table 3.5).  
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Table 3.5. Sites of primary tumors 
Tumor (T) sites 
SCC 
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total 
n=60 (100%) 
Rt. main bronchus 1 (16.7) 7 (15.5) 2 (22.2) 10 (16.7) 
Lt. main bronchus 1 (16.7) 6 (13.3) 0 (0) 7 (11.7) 
Rt. upper lobe 2 (33.3) 11 (24.4) 3 (33.3) 16 (26.7) 
Lt. upper lobe 0 (0) 7 (15.5) 3 (33.3) 10 (16.7) 
Middle lobe 0 (0) 2 (4.4) 0 (0) 2 (3.3) 
Rt. lower lobe 1 (16.7) 6 (13.3) 1 (11.1) 8 (13.3) 
Lt. lower lobe 1 (16.7) 6 (13.3) 0 (0) 7 (11.7) 
 
In ADCs patients, the ratio of right to left side tumors was 1.37/1. 39.9% of primary 
tumors (18 patients) were in upper lobes. 28.8% of primary tumors (13 patients) were in 
main bronchi. 26.6% of primary tumors (12 patients) were in lower lobes. Two patients 
(4.4%) had primary tumors in the middle lobes of the lung.  
In groups of SCCs, primary tumors originated equally in both sides of main bronchi (2 
patients), upper lobes (2 patients) and lower lobes (2 patients). Ratio of right to left sided 
tumors was 2/1. In groups of BACs, 66.6% of primary tumors (6 patients) were in upper 
lobes. Two patients (22.2%) had tumors in right main bronchi. One patient (11.1%) had 
tumor in right lower lobe. Ratio of right to left sided tumors was 1.5/1. 
Table 3.6. Mean size of primary tumors  
Types of 
pathology 
Male Female Total 
No. of 
patients 
Mean T sizes 
(mm) 
No. of 
patients 
Mean T sizes 
(mm) 
No. of 
patients 
Mean T sizes 
(mm) 
SCC 6 55.3 0 0 6 55.3 
ADC  30 51.3 15 41 45 48.1 
BAC 6 51.7 3 36.7 9 46.7 
Total 42 51.9 18 40.2 60 48.6 
 
As shown in Table 3.6, the average size of primary tumors was 48.6 mm. The mean size of 
tumors in male patients was 51.9 mm, being larger than tumors in female patients who had 
a mean of 40.2 mm. The mean size of tumors in groups of SCCs, ADCs and BACs were 
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55.3 mm, 48.1 mm and 48.6 mm, respectively. Male patients with SCCs had the largest 
tumor size (55.3 mm). Meanwhile, female patients with BACs had the smallest mean size 
of primary tumor (36.7 mm). 
3.2.3.2. Regional lymph nodes (N) 
Table 3.7. Sites of involved regional lymph nodes  
Regional lymph nodes (N) 
SCC  
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total number 
(% of Ns) 
Upper paratracheal 0 (0) 5 (8.9) 0 (0) 5 (6.7) 
Lower paratracheal 1 (12.5) 7 (12.5) 0 (0) 8 (10.7) 
Sub-aortic  2 (25) 5 (8.9) 1 (9.1) 8 (10.7) 
Para-aortic  3 (37.5) 24 (42.8) 8 (72.7) 35 (46.7) 
Sub-carinal 1 (12.5) 8 (14.2) 1 (9.1) 10 (13.3) 
Hilar 1 (12.5) 4 (7.1) 1 (9.1) 6 (8) 
Scalene  0 (0) 1 (1.7) 0 (0) 1 (1.3) 
Supraclavicular  0 (0) 2 (3.4) 0 (0) 2 (2.6) 
Total number (% of Ns) 8 (100) 56 (100) 11 (100) 75 (100) 
 
Involved regional lymph nodes were defined by chest CT scan with contrast. There were 
total of 75 lymph nodes which were recorded in 60 patients. Middle mediastinal lymph 
nodes were more commonly seen such as para-aortic (46.7%) and sub-aortic (10.7%) 
regions. Superior mediastinal lymph nodes which consisted of upper paratracheal and 
lower paratracheal nodes were seen in 17.4% of all cases. Inferior mediastinal (sub-carinal 
nodes) and hilar lymph nodes occupied 13.3% and 8%, respectively. Scalene and 
supraclavicular lymph nodes were rarely seen (3.9%) and found in ADC tumors only.  
Table 3.8. Mean size of regional lymph nodes  
Types of 
pathology 
Male Female Total 
No. of 
patients 
Mean N 
size (mm) 
No. of 
patients 
Mean N 
size (mm) 
No. of 
patients 
Mean N 
size (mm) 
SCC 6 32 0 0 6 32 
ADC  30 26.5 15 32.7 45 28.3 
BAC 6 17.5 3 26.7 9 20.6 
Total 42 25.9 18 31.6 60 27.5 
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In general, mean size of involved lymph nodes in patients of SCCs (32 mm) was larger 
than in patients of ADCs (28.3 mm) and BACs (20.6 mm).The mean size of lymph nodes 
in male patients was 25.9 mm, being smaller than lymph nodes in female patients whom 
had a mean of 31.6mm. Male patients with SCCs had the largest node size (32mm) while, 
male patients with BACs had the smallest (17.5 mm). 
3.2.3.3. TNM stage 
Table 3.9. TNM stage 
Stage 
IIIA  IIIB 
T2N2 T3N1 T3N2  T3N3 T4N0 T4N1 T4N2 T4N3 
N (%) 6 (10) 3 (5) 25 (41.7)  3 (5) 4 (6.7) 4 (6.7) 12 (20) 3 (5) 
Total 34 (56.7)  26 (43.3) 
 
In staging of primary tumors (T stages), there were six patients (10%) of T2, thirty-one 
patients (51.7%) of T3, and twenty-three patients (38.3%) of T4. In staging of involved 
lymph nodes (N stages), there were four patients (6.7%) of N0, seven patients (11.7%) of 
N1, forty-three patients (71.7%) of N2 and six patients (10%) of N3. Therefore, thirty four 
patients (56.7%) were classified as stage IIIA and 26 patients (43.3%) as stage IIIB. In 
stage IIIA, most patients (73.5%) were classified as T3N2M0. In stage IIIB, patients 
classified as T4N2M0 predominated with 46.2%.  
Table 3.10. Stages of disease, pathology and gender of patients 
Stages  Gender 
SCC 
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total 
n=60 (100%) 
IIIA (n= 34) 
Male 4 (66.7) 15 (33.3) 5 (55.5) 24 (40) 
Female 0 (0) 8 (17.8) 2 (22.2) 10 (16.7) 
IIIB (n=26) 
Male 2 (33.3) 15 (33.3) 1 (11.1) 18 (30) 
Female 0 (0) 7 (15.5) 1 (11.1) 8 (13.3) 
 
Proportion of stage IIIA patients were 57.1% and 55.6%, respectively, in male and female 
patients. In three subgroups of pathology, there were more patients with stage IIIA in 
SCCs (66.7%) and BACs (77.8%) than in patients with ADCs (51.1%).  
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3.2.4. Treatment characteristics 
3.2.4.1. Radiotherapy 
Table 3.11. Characteristics of radiotherapy 
Types of 
pathology 
Mean V20 of 
lung (%) 
Mean field 
length (cm) 
Mean spinal cord 
dose (Gy) 
Mean interruption 
time (days) 
SCC (n=6) 33.3 14.1 37.2 3.8 
ADC (n=45) 27.9 13.9 40.4 4.3 
BAC (n=9) 25.1 13.5 40.4 3.2 
Total (n=60) 28 13.9 40.1 4.1 
 
Total dose of radiotherapy: Fifty-six patients (93.3%) received 60Gy as protocol, two 
patients (3.3%) received 50Gy, one patient (1.7%) received 56Gy and one patient (1.7%) 
received 54Gy. All these four patients were ADCs. The reasons for not completing 
radiotherapy were treatment-related complication (one patient) and patient refusal (three 
patients). 
Planning target volume and field length: The median volume of planning target volumes 
(PTV) of all patients was 540.5 cm
3 
(ranging from 191.5 cm
3
 to 1197.3 cm
3
). The mean of 
field length in patients with SCCs, ADCs and BACs were 14.1 cm, 13.9 cm and 13.5 cm, 
respectively. 
Organ of interests: Lung and spinal cord were two most important critical organs. All the 
plans of radiotherapy were checked with V20 of the lung and maximal dose to spinal cord. 
Mean percentage of the total volume of both lungs minus the PTV receiving greater than 
20Gy (V20) of all patients was 28% (ranging from 15 – 42%). Mean V20 of SCCs was 
highest with 33.3%. Mean V20 in ADCs and BACs were 27.9% and 25.1%, respectively. 
Mean of spinal cord doses of all patients was 40.1Gy (ranging from 18 – 44Gy). Mean 
spinal cord dose in SCCs was lowest with 37.2Gy. Mean spinal cord dose in ADCs and 
BACs patients were higher with the same dose of 40.4Gy. 
Treatment time and interruptions: The mean duration of radiotherapy in all patients was 
6.4 weeks (ranging from 5.1 to 8.3 weeks). Thirty-six patients (60%) had treatment 
interruptions during course of radiotherapy. Among these, twenty one patients had one 
treatment interruption. Eleven patients had 2. Three patients had 3 and one patient had 4 
treatment interruptions. The average duration of radiotherapy interruption was 4.1 days 
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(range from 1 to 11 days). The mean interruption duration in patients with SCCs, ADCs 
and BACs were 3.8, 4.3 and 3.2 days, respectively. Reasons for treatment interruptions 
were mostly due to machine break-downs and on public holidays. Only one patient had an 
interruption due to grade 4 side effects – i.e. radiation esophagitis. 
3.2.4.2. Chemotherapy 
Table 3.12. Characteristics of chemotherapy 
Chemotherapy 
characteristics 
SCC 
n=6 (100%) 
ADC 
n=45 (100%) 
BAC 
n=9 (100%) 
Total 
n=60 (100%) 
5 cycles completed 0 4 (8.9) 1 (11.1) 5 (8.3) 
6 cycles completed 6 (100) 41 (91.1) 8 (88.9) 55 (91.7) 
Delayed treatment 3 (50) 16 (35.5) 4 (44.4) 23 (38.3) 
Dose reduction  1 (16.7) 7 (15.6) 3 (33.3) 11 (18.3) 
 
Cycles completed: Fifty-five patients (91.7%) completed six cycles of chemotherapy as 
protocol including six patients (100%) of SCCs, forty-one patients (91.1%) of ADCs and 
eight patients (88.9%) of BACs. Five patients (8.3%) stopped chemotherapy at fifth cycle 
of which four patients had ADCs and one patient had BAC. The reasons for not 
completing chemotherapy were treatment-related complications (including four patients 
with esophagitis and one with neutropenia). 
Treatment delay: Twenty-three patients (38.3%) had delayed doses during the 
chemotherapy cycles that extended over a period of six weeks. The rate of delayed doses in 
patients with SCCs, ADCs and BACs was 50%, 35.5% and 44.4% in respectively. The 
reasons for delayed chemotherapy were treatment-related complications (fourteen patients 
with grade 3 or 4 esophagitis, two patients with grade 3 dermatitis and one patient with 
grade 3 neutropenia). The remainder (6 patients) delayed one to several days due to their 
personal reasons. 
Dose reduction: A dose reduction of chemotherapy was required in 11 patients (18.3%). 
The reasons for reducing dose of chemotherapy were drug-related hematologic side effects 
(eight patients with grade 2 or 3 neutropenia and two patients with grade 2 
thrombocytopenia) and radiotherapy-related complication (one patient with grade 4 
esophagitis). The rate of dose reduction of chemotherapy in patients with SCCs, ADCs and 
BACs were 16.7%, 15.6% and 33.3%, respectively. 
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3.2.5. Safety and tolerability  
Hematological, liver and renal function toxicities 
Table 3.13. Hematological, liver and renal function toxicities 
Toxicities 
Grade 0      
n (%) 
Grade 1     
n (%) 
Grade 2   
n (%) 
Grade 3   
n (%) 
Grade 4 
n (%) 
Anemia 23 (38.3) 27 (45) 8 (13.3) 2 (3.3) 0 (0) 
Leukopenia 21 (35) 19 (31.7) 13 (21.6) 6 (10) 1 (1.7) 
Neutropenia 37 (61.7) 14 (23.3) 7 (11.7) 1 (1.7) 1 (1.7) 
Thrombocytopenia 55 (91.7) 3 (5) 2 (3.3) 0 (0) 0 (0) 
SGOT/SGPT  37 (61.7) 18 (30) 5 (8.3) 0 (0) 0 (0) 
Serum creatinine 48 (80.0) 12 (20) 0 (0) 0 (0) 0 (0) 
 
According to classification of NCI-CTC version 2.0, common maximal hematological 
toxicities consisted of leukopenia (65%), anemia (61.7%) and neutropenia (38.3%). 
Thrombocytopenia (8.3%) was rarely seen with three patients in grade 1 and two patients 
in grade 2. In addition, hepatic dysfunction (SGOT/SGPT increase) occurred not very 
frequently with 30% in grade 1 and 8.3% in grade 2. Serum creatinine increase was mild 
and not common with twelve patients (20%) in grade 1 toxicities. As shown in Table 3.13, 
grade 3 or 4 toxicities were presented only in two patients (3.3%) with anemia, seven 
patients (11.7%) with leucopenia and two patients (3.3%) with neutropenia. No patient had 
severe toxicities of thrombocytonia, liver or renal function. 
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Non-hematological toxicities 
Table 3.14. Non-hematological toxicities 
Toxicities 
Grade 0      
n (%) 
Grade 1     
n (%) 
Grade 2   
n (%) 
Grade 3   
n (%) 
Grade 4 
n (%) 
Nausea/ Vomiting 37 (61.7) 6 (10) 16 (26.7) 1 (1.7) 0 (0) 
Fatigue/ Anorexia 12 (20) 12 (20) 22 (36.7) 13 (21.7) 1 (1.7) 
Alopecia  35 (58.3) 11 (18.3) 14 (23.3) 0 (0) 0 (0) 
Dermatitis 31 (51.7) 7 (11.7) 20 (33.3) 2 (3.3) 0 (0) 
Weight loss 36 (60) 20 (33.3) 4 (6.7) 0 (0) 0 (0) 
Cough/ Dyspnea 33 (55) 9 (15) 16 (26.7) 2 (3.3) 2 (3.3) 
Esophagitis 20 (33.3) 3 (5) 23 (38.3) 13 (21.7) 1 (1.7) 
 
Non-hematological side effects were usually related to radiation therapy. They included 
fatigue or anorexia (80%), esophagitis (66.7%), dermatitis (48.3%), alopecia (41.7%), 
weight loss (40%) and nausea or vomiting (28.3%) during the treatment time.  As severe 
adverse events, fourteen patients (23.3%) presented with grade 3 or 4 of dysphagia or 
odynophagia due to radiation esophagitis. These patients required intravenous nutrition. 
One patient had grade 4 of dysphagia which progressed to fibrosis and required esophageal 
dilatation. Severe nausea or vomiting was uncommon with one patient (1.7%) in grade 3. 
Radiation dermatitis was seen in just two cases (3.3%) with severe grade.  
As acute and/or sub-acute complication, cough and/or dyspnea symptoms occurred in 27 
patients (45%) during the treatment and some patients kept suffered persistently after 
treatment. Of these, four patients (6.6%) had grade 3 or 4 of cough or dyspnea (with two 
patients in each grade). After treatment, there were four patients (6.7%) who presented 
with severe dyspnea (two patients), neutropenia infection (one patient) or severe cachexia 
(one patient) and passed away within the first three months. These should be due to 
irreversible treatment-related complications or disease progression. 
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3.2.6. Responses to treatment 
Table 3.15. Response rates  
Subtypes of 
pathology 
Complete 
responses 
Partial 
responses 
Stable 
diseases 
Progressive 
diseases 
SCC  
(n=5/100%) 
0 
(0%) 
3 
(60%) 
1 
(20%) 
1 
(20%) 
ADC  
(n=42/100%) 
2 
(4.8%) 
22 
(52.4%) 
11 
(26.2%) 
7 
(16.7%) 
BAC  
(n=9/100%) 
1 
(11.1%) 
4 
(44.4%) 
3 
(33.3%) 
1 
(11.1%) 
Total  
(n=56/100%) 
3 
(5.4%) 
29 
(51.8%) 
15 
(26.8%) 
9 
(16%) 
 
There were four patients (6.7%) died at other hospitals or at home before coming back to 
us for assessment. The reasons were due to severe adverse events or disease progression. 
According to criteria of RECIST (Appendix E), overall response rate of all assessable 
patients was 57.2%. There were 5.4% patients with complete responses and 51.8% with 
partial responses. 26.8% had stable diseases and the rest had progressive disease.  
In patients with SCCs, no patient had complete response and three patients (60%) had 
partial response. In patients with ADCs, 24 patients (57.2%) gained overall responses, 
including two patients (4.8%) with complete responses and twenty-two patients (52.4%) 
with partial responses. In patients with BACs, five patients (55.5%) gained objective 
responses, including one patient (11.1%) with complete response and four patients (44.4%) 
with partial response.  
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3.2.7. Survival time 
Figure 3.7. Progression-free survival curve by Kaplan-Meier method 
 
 
Figure 3.8. Overall survival time curve by Kaplan-Meier method 
 
 
The last day of follow up was set on December 1
st
, 2012. That means, the last patient who 
was recruited to the study had at least six months of follow-up. With the median 12.7 
months of follow up, 36.7% of patients were still alive, two patients missing of follow-up 
and 60% of patients have deceased. Of these, 11.1% (4 patients) died within the first three 
months due to irreversible treatment-related complications, 22.2% (8 patients) had early 
local progression and/or metastases in the first six months. In addition, 11.1% (4 patients) 
died of non-related lung cancer causes, including two cerebrovascular strokes, one 
myocardial infarction and one hepatocellular carcinoma. 
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Overall survival (OS) is defined as a time from the first day of radiotherapy till the death of 
any cause. Progression-free survival (PFS) is defined as a time from the first day of 
radiotherapy till disease progression, death or last known follow-up. In this study, the 
median of progression-free survival and overall survival were 10.6 months and 14.4 
months in respectively (both ranging from 1.9 months to 37.8 months). Overall survival 
rates at 12 and 24 months were 54% and 37% in respectively. 
 
3.2.7.1. Survival time according to gender of patients 
Table 3.16. Survival time of male and female patients   
Gender No. of patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
Males 42 10.5 
0.8 
12.6 
0.6 
Females 18 13.7 17.5 
 
Figure 3.9. Progression-free survival curves of male and female patients 
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Figure 3.10. Overall survival curves of male and female patients 
 
 
Both progression-free survival and overall survival time in female patients were more 
favorable than male patients. Median survival time to progression in male and female 
patients was 10.5 months and 13.7 months in respectively, leading to a hazard ratio of 0.9 
(95% CI, 0.43 – 1.89) but not significantly different (p = 0.8, log-rank test). The median of 
overall survival time in male and female patients were 12.6 months and 17.5 months in 
respectively, leading to a hazard ratio of 0.8 (95% CI, 0.4 – 1.7) and not statistically 
significant (p = 0.6, log-rank test). 
 
3.2.7.2. Survival time according to age group of patients 
Table 3.17. Survival time of patients <60, 60–69 and >69 years of age 
Age of patients  No. of 
patients 
Median PFS 
(months) 
P-value Median OS 
(months) 
P-value 
< 60 years old 36 13.1 
0.42 
17.5 
0.28 60-69 years old 15 10.6 22.4 
> 69 years old 9 4.5 6.6 
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Figure 3.11. Progression-free survival curves of patients <60, 60–69 and >69 years old 
 
 
 
Figure 3.12. Overall survival curves of patients <60, 60–69 and > 69 years old 
 
 
We divided all patients into three age subgroups: under 60, 60 to 69 and older than 69 
years old. The median of progression-free survival and overall survival time was greatest 
in patients with age from 60-69 years old (10.6 and 22.4 months, respectively). In contrast, 
the patients older than 69 years old had poorest survival with median time to progression 
of 4.5 months and median overall survival time of 6.6 months. However, the differences in 
both PFS and OS time among three groups were not statistically significant (p > 0.05, log-
rank test). When compared age group under 60 and 60-69 years old, the median time to 
progression was not dissimilar with the hazard ratio of 1 (95% CI, 0.5 – 2.3) (p = 0.9, log-
rank test).  
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3.2.7.3. Survival time according to subtypes of pathology 
Table 3.18. Survival time of patients with SCCs, ADCs and BACs 
Subtypes of 
pathology 
No. of patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
SCCs  6 4.7 
0.38 
10.4 
0.4 ADCs 45 10.6 14.4 
BACs 9 13.7 17.8 
 
Figure 3.13. Progression-free survival curves of patients with SCCs, ADCs and BACs 
 
 
 
Figure 3.14. Overall survival curves of patients with SCCs, ADCs and BACs 
 
 
In three subtypes of histology, the median of progression-free survival and overall suvival 
time was most favorable in patients with BACs (13.7 and 17.8 months, respectively)and 
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poorer in patients with SCCs (4.7 and 10.4 months, respectively). The median time to 
progression in patients with SCCs was shorter than patients with ADCs (4.7 versus 10.6 
months), leading a hazard ratio of 1.6 (95% CI, 0.6 – 4.1) but the difference was not 
statistically significant (p=0.4, log-rank test).  
The median time to progression in patients with BACs was more favorable than patients 
with ADCs (13.7 versus 10.6 months), leading a hazard ratio of 0.8 (95% CI, 0.5 - 1.3). 
The difference wasnot statistically significant (p=0.38, log-rank test). Similarly, overall 
survival time in patients with BACs was more favorable than patients with ADCs (17.8 
versus 14.4 months), leading a hazard ratio of 0.8 (95% CI, 0.5 – 1.3). The difference was 
not statistically significant (p=0.4, log-rank test). 
 
3.2.7.4. Survival time according to TNM stages 
Primary tumor (T) stages 
Table 3.19. Survival time of patients with T2, T3 and T4 
Tumor stages 
No. of 
patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
 T2 6 14.8 
0.09 
25.4 
0.05  T3 32 10.1 12.6 
 T4 22 6.8 10.5 
 
Figure 3.15. Progression-free survival curves of patients with T2, T3 and T4 
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Figure 3.16. Overall survival curves of patients with T2, T3 and T4 
 
 
There were 6 patients with T2 (i.e. T2N2M0 – stage IIIA) who had most favorable 
outcome. Their median time to progression and overall survival were 14.8 and 25.4 
months, respectively. The median time to progression in patients with T3 tumors was more 
favorable than patients with T4 (10.1 versus 6.8 months). The differences among three 
subgroups were not statistically significant (p=0.09, log-rank test). The median survival 
time in patients with T2, T3 and T4 were 25.4, 12.6 and 10.5 months in respectively. The 
difference was not statistically significant (p=0.05, log-rank test). 
 
Regional lymph nodes (N) 
Table 3.20. Survival time of patients with N0, N1, N2 and N3 
Node stages  
No. of 
patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
 N0 4 11.4 
0.3 
11.4 
0.5 
 N1 7 8.9 11.6 
 N2 43 10.2 17.5 
 N3 6 6.6 9 
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Figure 3.17. Progression-free survival curves of patients with N0, N1, N2 and N3 
 
 
Figure 3.18. Overall survival curves of patients with N0, N1, N2 and N3 
 
 
The median of progression-free survival time in patients with lymph nodes at stage of N1 
was shorter than both two groups of N0 and N2 (8.9 months versus 11.4 and 10.2 months). 
The median overall survival time in patients with N0, N1 and N2 were 11.4, 11.6 and 17.5 
months in respectively. Patients with N3 stage had poorest outcome in terms of median 
time to progression and overall survival (6.6 and 9 months, respectively). The differences 
in progression-free and overall survival time among four groups were not statistically 
significant (p>0.05, log-rank test). 
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Survival time according to stages of diseases 
Table 3.21. Survival time of patients with stage IIIA and IIIB 
Stages of 
cancer 
No. of 
patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
IIIA 34 13.7 
0.11 
22.4 
0.08 
IIIB 26 6.4 10.5 
 
Figure 3.19. Progression-free survival curves of patients with stage IIIA and IIIB 
 
 
Figure 3.20. Overall survival curves of patients with stage IIIA and IIIB 
 
 
The median time to progression in patients with NSCLC stage IIIA was more favorable 
than patients with stage IIIB (13.7 versus 6.4 months), leading a hazard ratio of 1.7 (95% 
CI, 0.9 – 3.3). The difference wasnot statistically significant (p=0.11, log-rank test). The 
median of overall survival time in patients with stage IIIA and IIIB were 22.4 months and 
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
C
u
m
lu
la
tiv
e
 S
u
rv
iv
a
l
0 6 12 18 24 30 36 42
Survival time (month)
IIIA IIIB
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
C
u
m
lu
la
ti
v
e
 S
u
rv
iv
a
l
0 6 12 18 24 30 36 42
Survival time (month)
IIIA IIIB
50 
 
10.5 months, respectively. The differences in overall survival time between stage IIIA and 
stage IIIB patients were not statistically significant (p=0.08, log-rank test) with a hazard 
ratio of 1.8 (95% CI, 0.94 – 3.54). 
 
3.2.7.5. Survival time according to pretreatment performance status  
Table 3.22. Survival time of patients with KPS 100, 90 and 80 
Performance 
status at baseline 
No. of 
patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
KPS 100 14 13.4 
<0.001 
20.1 
<0.001 KPS 90 26 10.6 13.0 
KPS 80 20 5.0 7.7 
 
Figure 3.21. Progression-free survival curves of patients with KPS 100, 90 and 80 
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Figure 3.22. Overall survival curves of patients with KPS 100, 90 and 80 
 
 
The median of progression-free survival time in patients with KPS of 100, 90 and 80 were 
13.4 months, 10.6 months and 5.0 months, respectively. The differences in progression-
free survival time among three groups were statistically significant (p<0.001, log-rank 
test). The median of overall survival time in patients with KPS 100 was most favorable 
with 20.1 months. Patients with KPS 80 had least favorable with the median time at 7.7 
months. Patients with KPS 90 had median overall survival time of 13.0 months. Similarly, 
the differences in overall survival time among three groups were statistically significant 
(p<0.001, log-rank test). 
 
3.2.7.6. Survival time according to pretreatment weight loss  
Table 3.23. Survival time of patients with pretreatment weight loss <5% and 5-10% 
Baseline weight loss 
No. of 
patients 
Median PFS 
(months) 
P-value 
Median OS 
(months) 
P-value 
Normal or under 5% 40 13.7 
0.04 
20.5 
0.01 
From 5-10% 20 7.2 10.1 
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Figure 3.23. Progression-free survival curves of patients with weight loss < 5% and 5-10% 
 
 
Figure 3.24. Overall survival curves of patients with weight loss <5% and 5-10% 
 
 
The median of progression-free survival time in patients with weight loss under 5% and 
from 5 - 10% were 13.7 and 7.2 months, respectively. The differences in progression-free 
survival time between two groups were statistically significant (p=0.04, log-rank test). The 
median of overall survival time in patients with weight loss under 5% was 20.5 months. 
Patients with weight loss from 5 - 10% had less favorable survival time at 10.1 months. 
The differences in overall survival time between two groups were statistically significant 
(p=0.01, log-rank test). 
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3.2.7.7. Prognostic factors to survival time 
Table 3.24. Cox proportional hazards regression model for survival 
Variables 
Progression-free survival Overall survival 
Hazard ratio (95% CI) P-value   Hazard ratio (95% CI) P-value   
Female / Male 0.9 (0.43 – 1.89) 0.8 0.8 (0.4 – 1.7) 0.6 
Age of patients (years old) 
> 69 / 60 – 69  1.5 (0.6 – 3.9) 0.4 1.4 (0.9 – 2.1) 0.11 
> 69 / < 60 1.3 (0.9 – 1.9) 0.2 1.7 (0.6 – 4.6) 0.3 
60 – 69 / < 60 1 (0.5 - 2.3) 0.9 1.1 (0.5 – 2.4) 0.9 
Subtypes of pathology 
SCC / ADC 1.6 (0.6 – 4.1) 0.4 1.5 (0.6 – 3.8) 0.43 
BAC / ADC 0.8 (0.5 - 1.3) 0.38 0.8 (0.5 – 1.3) 0.4 
BAC / SCC 0.3 (0.08 -1.2) 0.09 0.3 (0.09 – 1.3) 0.11 
Stage of cancer 
IIIB / IIIA 1.7 (0.9 – 3.3) 0.11 1.8 (0.94 – 3.54) 0.08 
Performance status at baseline 
KPS 80/ KPS 100 2.2 (1.3 – 3.8) 0.003 2.8 (1.5 – 5.0) 0.001 
KPS 80/ KPS 90 3.1 (1.4 – 6.6) 0.004 3.1 (1.5 – 6.7) 0.003 
KPS 90/ KPS 100 1.46 (0.6 – 3.8) 0.44 1.7 (0.6 – 4.5) 0.3 
Weight loss at baseline 
5-10% / < 5% 2.1 (1 – 4.2) 0.043 2.4 (1.2 – 4.9) 0.015 
 
We analysed the relationship of progression-free and overall survival time to a variety of 
factors as possible predictive value. They included gender, age of patients, subtypes of 
histology, stage of cancer, performance status and weight loss of patients at the time of 
diagnosis. As shown in Table 3.24, the time to progression and overall survival were 
favorable for female patients, patients with age < 70 years old and stage IIIA, but not 
statistically significant.  
However, the differences in progression-free survival time between patients with KPS 100 
and KPS 80, between KPS 90 and KPS 80 were statistically significant with hazard ratios 
of 2.2 (95% CI from 1.3 to 2.8) and 3.1 (95% CI from 1.4 to 6.6), respectively. In terms of 
overall survival time, these differences were also significant with hazard ratios of 2.8(95% 
CI from 1.5 to 5.0) and 3.1 (95% CI from 1.5 to 6.7), respectively. 
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In addition, the differences in the time to progression and overall survival between patients 
with weight loss <5% and patients with weight loss 5 - 10% were significant with hazard 
ratios of 2.1 (95% CI from 1 to 4.2) and 2.4 (95% CI from 1.2 to 4.9). Therefore, 
pretreatment performance status and weight loss were considered as predictive factors for 
progression-free survival time and overall survival in this study. 
 
3.2.8. Recurrences and metastases 
Table 3.25. Patterns of failure to treatment 
Failures  
SCCs  
n=6 (100%) 
ADCs  
n=45 (100%) 
BACs  
n=9 (100%) 
Total  
n=60 (100%) 
Local recurrences 4 (66.7) 14 (31.1) 2 (22.2) 20 (33.3) 
Distant metastases 0 (0) 19 (42.2) 4 (44.4) 23 (38.3) 
 
The primary tumor site and/or the chest were the first sites of failure in 20 patients 
(33.3%), including 6 patients (10%) with both local recurrence and distant metastases. The 
local recurrence frequency was highest in patients with SCCs (four patients – 66.7%). It 
was relatively lower in patients with ADCs (fourteen patients – 31.1%) and BACs (two 
patients – 22.2%). Twenty-three patients (38.3%) had distant metastases. The rate of 
distant metastases was higher in ADCs (19 patients – 42.2%) and BACs (four patients- 
44.4%). However, no patient with SCCs presented with distant metastasis. 
Among patients with metastases, brain was the most common site with thirteen patients 
(56.5%). Other frequent sites included bony lesions (nine patients – 39.1%), liver (four 
patients – 17.4%) and lungs (three patients, one of multiple lesions in both sides and two of 
contralateral lesions – 13%). There was one patient who developed metastases to brain and 
then, to abdominal lymph nodes subsequently.  
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4. DISCUSSION 
 
4.1. Characteristics of lung cancer patients 
This was a prospective study which included all patients who presented to the Department 
of Oncology, Cho Ray hospital, Ho Chi Minh city, Vietnam with lung cancer from March 
1
st
, 2009 to March 1
st
, 2012. Cho Ray was one of two main hospitals located on Ho Chi 
Minh city and receives cancer patients for this city and almost all provinces from the South 
Vietnam. Therefore, the results of this study might reflect some characteristics of lung 
cancer patients in Vietnam. 
4.1.1. Age and gender  
During the three years, there were 1,158 patients with lung cancer including 821 males and 
337 females admitted to this hospital. The ratio of male to female patients was 
approximately 7: 3. The median age of all patients was 56 years old (ranging from 20 to 87 
years of age). The median ages at the time of diagnosis of male and female population 
were 57 and 55 years old in respectively.  
Age difference between men and women in Cho Ray was consistent with the results of a 
study in Poland. This community-based cancer registry reported that age at diagnosis was 
younger for women (60 years old) compared to men (62.2 years old) and more women 
were under 50 years old to men (23% and 12%) (Radzikowska et al. 2002). 
In addition, the age of patients in Vietnam was significantly lower than in many studies in 
Western countries. Worldwide during 2002, Ezzati reported that 5% of lung cancer cases 
were diagnosed among people aged 0 to 44 years, 14% in the 45 to 54 age group, 25% in 
the 55 to 64 age group, and 55% among those aged 65 years and over (Ezzati et al. 2003). 
While in Cho Ray, these figures were 12.1%, 30.7%, 32.6% and 24.6% in respectively.  
In United States, using SEER database from 1975 – 1999, Fu et al. found that median age 
at the time of diagnosis was 66 years old for both men and women. Women accounted for 
35.8% and occupied 40.9% in patients under 50 years old (Fu et al. 2005).  
In the province of Oulu (Finland), Makitaro et al. conducted the population-based study 
with 602 patients and reported the mean age of 67.7 years (Makitaro et al. 2002).  
In Tokushima Prefecture - Japan, Kanematsu et al. recruited 2183 lung cancer patients in 
Tokushima University Hospital and Tokushima Prefectural Central Hospital to review the 
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epidemiologic and clinical features of lung cancer. Patients older than 75 years old 
occupied 32% and the mean age was 70 years old (Kanematsu et al. 2010). Higher 
smoking rate and shorter life expectancy might be one of reasons explained why lung 
cancer patients in Vietnam were younger than more developed countries.  
Table 4.1. Some characteristics of lung cancer patient in Finland, Japan and Vietnam 
Characteristics 
Makitaro et al.       
(1990-1992) 
Kanematsu et al.   
(1999-2009) 
Cho Ray         
(2009-2011) 
All patients (n, %) 602 (100) 2183 (100) 1158 (100) 
      Male  
      Female 
510 (85) 
92 (15) 
1591 (73) 
592 (27) 
821 (70.9) 
337 (29.1) 
Mean age 68 70 56 
Histological type (n, %) 
      Small cell carcinoma 
      Adenocarcinoma   
      Squamous cell carcinoma  
      Large cell carcinoma  
      Others 
      No histology 
 
121 (20) 
135 (22) 
204 (34) 
23 (4) 
33 (6) 
86 (14) 
 
278 (13) 
1112 (51) 
545 (25) 
69 (3) 
179 (8) 
0 
 
57 (4.9) 
745 (64.3) 
131 (11.3) 
9 (0.8) 
216 (18.6) 
0 
TNM staging (n, %) 
Stage I 
      Stage II 
      Stage III 
      Stage IV 
519 (86) 
97 (19) 
21 (4) 
185 (36) 
216 (41) 
2110 (97) 
684 (32) 
140 (6) 
608 (28) 
678 (31) 
1158 (100) 
26 (2.2) 
101 (8.7) 
449 (38.8) 
582 (50.3) 
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4.1.2. Pathological characteristics 
As shown in Table 4.1, adenocarcinomas (64.3%) were the most common histological 
diagnosis in group of non-small cell lung cancer in our database while small cell lung 
cancer (SCLC) was not common (4.9%). The geographic distribution of patients with 
many living far from Ho Chi Minh city and a great proportion of late stage lung cancer 
patients could explain the small number of SCLC cases in Cho Ray. Many patients might 
have progressive disease and die before going to hospital.  
In Japan, Kanamitsu et al. reported that non-small cell lung cancer (NSCLC) and small cell 
lung cancer (SCLC) constituted 87% and 13%, respectively. With regard to NSCLC, the 
predominant histological type was adenocarcinoma (51%), followed by squamous cell 
carcinoma (25%), large cell carcinoma (3%) and others (8%) (Kanematsu et al. 2010). 
In Finland, squamous cell carcinoma (34%) was also the most common subtype of 
pathology, consistent to other European trials. Less common subtypes of histology 
included adenocarcinoma (22%), small cell carcinoma (20%) and large cell carcinoma 
(4%) (Makitaro et al. 2002).  
There was considerable variation in the different histological types of lung cancer between 
countries. In United States, NSCLC accounted for approximately 80% to 85% of all cases 
(Jemal et al. 2008). Squamous cell carcinoma accounted for 45% in Europe and 
approximately 30% of all lung cancer in the United States (Travis et al. 1995).  
In Germany, the most frequently histological subtype of lung cancer was non-small cell 
lung cancer (approximately 75% of lung cancers) and majority of NSCLC were squamous 
cell carcinomas (Huber et al. 2006). 
In contrast, adenocarcinoma tends to be the most common histology subtype in women and 
this proportion continues to increase over time in Asian countries (Perng et al. 1996, 
Yoshimi et al. 2003). Adenocarcinoma was the most prevalent form of lung cancer in 
younger males (under 50 years old) and in women of all ages, in never smokers and in 
former smokers (Ramalingam et al. 1998). 
 
4.1.3. Staging characteristics 
In current study, there were 2.2%, 8.7%, 38.8% and 50.3% of patients who had lung cancer 
stages of I, II, III and IV in respectively. With regard to non-small cell lung cancer 
(NSCLC), 89.1% of patients had advanced (III or IV) stages. Common sites for metastases 
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in patients with lung cancer were brain (39.1%), liver (22.5%) and lung and/or pleura 
(19.7%). Among patients with small cell lung cancer (SCLC), 79% were diagnosed at 
extended stages.  
Kanematsu et al. reported a comparable percentage of patients with stage III (28%) and IV 
(31%) of lung cancer. More patients had early stages (I or II) than in Cho Ray series (41% 
versus 10.9%) (Kanematsu et al. 2010). 
As a population-based study, computed tomography (CT) was conducted only in 59% of 
patients and staging of the cancer were carried out for 86%. Of these, 36% and 41% of 
patients were diagnosed at stage III and IV, respectively (Makitaro et al. 2002). 
In the Surveillance, Epidemiology and End Results (SEER) 2004 registry in United States, 
29.7% of new NSCLC cases presented with stage III disease, of which 12.1% were stage 
IIIA and 17.6% were stage IIIB (Wisnivesky et al. 2005). 
 
4.2. Characteristics of patients with stage III non-small cell lung cancer 
There were 60 patients that satisfied the inclusion criteria and not committed to exclusion 
criteria to join this study. All patients received weekly paclitaxel (dose of 45mg/m
2
) and 
carboplatin (AUC=2) for 6 consecutive weeks. Concurrent radiotherapy to 60Gy was 
administered at five fractions per week for six consecutive weeks at 2Gy/fraction. 
There were several multicenter studies using the similar regimen in literature. From 1995 – 
1996, a multi-institutional phase II clinical trial was conducted in United States to evaluate 
the activity and toxicity of paclitaxel, carboplatin, and concurrent radiation therapy on 
patients with locally advanced NSCLC (Choy et al. 1998). Then, Belani et al. introduced a 
randomized phase II study to compare three different weekly schedules of the 
carboplatin/paclitaxel regimen for patients with advanced NSCLC (Belani et al. 2005).  
In Germany, a phase III trial was conducted to compare induction chemotherapy followed 
by either radiation alone or chemo-radiotherapy (Huber et al. 2006). As a similar trial, 
Vokes et al. evaluated whether induction chemotherapy before concurrent chemo-
radiotherapy would result in improved survival (Vokes et al. 2007). Recently, the West 
Japan Thoracic Oncology Group conducted a phase III study to compare the second 
generation regimens at full doses or the third generation regimens at reduced doses in 
concurrent chemo-radiotherapy setting for stage III NSCLC (Yamamoto et al. 2010). 
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In the duration of three years, we recruited 60 patients in one institution. With the 
comparable time, Choy et al. selected only 40 patients from six centers in United States. 
Other studies with longer recruitment time from 4-6 years had selected a larger number of 
patients from many sites onto their trials. 
Table 4.2. Summary of selected studies with chemoradiation alone or combined with 
induction/consolidation chemotherapy  
References 
(Phase) 
Period 
No. of 
Pts 
Induction 
Therapy 
Concurrent Therapy 
Consolidative 
Therapy 
Choy et al. 
(II)  
3/1995 – 
12/1996 
40 NA 66 Gy/ Pac/Carbo Pac/Carbo 
Belani et al. 
(II) 
2/1998 – 
6/2001 
91 Pac/Carbo 63 Gy NA 
74 Pac/Carbo 63 Gy/Pac/Carbo NA 
92 NA 63 Gy/Pac/Carbo Pac/Carbo 
Huber et al. 
(III) 
7/1997 – 
5/2002 
113 
99 
Pac/Carbo 
Pac/Carbo 
60 Gy 
60 Gy/ Pac/Carbo 
NA 
NA 
Vokes et al. 
(II)   
7/1998 – 
5/2002 
161 
170 
NA 
Pac/Carbo 
66 Gy/ Pac/Carbo 
66 Gy/ Pac/Carbo 
NA 
NA 
Yamamoto 
et al. (III) 
9/2001 – 
9/2005 
146 
147 
147 
NA 
60 Gy/MVP 
60 Gy/Irino/Carbo 
60 Gy/ Pac/Carbo 
MVP 
Irino/Carbo 
Pac/Carbo 
Cho Ray 
3/2009 – 
3/2011 
60 NA 60 Gy/ Pac/Carbo NA 
Abbreviations: NA, not applicable; Pac, paclitaxel; Carbo, carboplatin; Irino, Irinotecan; MVP: Mitomycin 
C, Vindesine, Cisplatin. 
 
4.2.1. Patient demography 
In general, patients who were selected to most concurrent chemo-radiotherapy trials were 
younger than patients in general population.  A retrospective analysis of all patients 
enrolled onto Southwest Oncology Group trials between 1993 and 1996 demonstrated that 
only 25% were 65 years or older (Hutchins et al. 1999). As shown in Table 4.3, mean age 
of patients in our trial was somewhat younger than patients in other studies.  
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Table 4.3. Characteristics of patients in concurrent chemoradiation studies with weekly 
Paclitaxel and Carboplatin 
References 
Choy et 
al. (1998) 
Belani et 
al. (2005) 
Huber et 
al. (2006) 
Vokes et 
al. (2007) 
Yamamoto 
et al. (2010) 
Cho Ray 
(2012) 
Induction 
Therapy 
NA NA Pac/Carbo NA NA NA 
Concurrent 
Therapy 
(dose in mg/m2) 
66Gy 
Pac(50) 
Carbo 
63Gy 
Pac(45) 
Carbo 
60Gy 
Pac(60) 
 
66Gy 
Pac(50) 
Carbo 
60Gy 
Pac(40) 
Carbo 
60Gy 
Pac(45) 
Carbo 
Consolidative 
Therapy 
Pac/Carbo Pac/Carbo NA NA Pac/Carbo NA 
Mean age (y/o)  60 75% < 70  62.38  63 63 58 
Sex (n/%) 
  Male  
  Female  
 
25 (62.5) 
15 (37.5) 
 
62 (67) 
30 (33) 
 
86 (86.9) 
13 (13.1) 
 
125 (69) 
57 (31) 
 
128 (87.1) 
19 (12.9) 
 
42 (70) 
18 (30) 
KPS (n/%)       
  90-100 19 (47.5) 
90 (97.8) 
70 (70) 82 (45) 65 (44.2) 43 (71.6) 
  80 21 (52.5) 20 (20) 94 (52) 81 (55.1) 17 (18.4) 
  70  2 (2.2) 6 (6)   
  No information   3 (3) 5 (3) 1 (0.7)  
Stage (n/%)  
  IIIA  
  IIIB  
  Not classified  
 
12 (30) 
28 (70) 
 
 
35 (38) 
57 (62) 
 
10 (10.1) 
88 (88.9) 
1 (1) 
 
87 (48) 
84 (46) 
13 (7) 
 
49 (33.3) 
98 (66.7) 
 
34 (56.7) 
26 (43.3) 
Histology (n/%) 
  ADC 
  SCC 
  Large cell 
  Mixed 
  Not classified 
 
8 (20) 
21 (52.5) 
9 (22.5) 
 
2 (5) 
 
32 (34.8) 
37 (40.2) 
9 (9.8) 
2 (2.2) 
12 (13) 
 
19 (19.2) 
62 (62.6) 
4 (4) 
3 (3) 
11 (11) 
  
62 (42.2) 
71 (48.3) 
 
54 (90) 
6 (10) 
Abbreviations: NA, not applicable; Pac, paclitaxel; Carbo, carboplatin. 
 
61 
 
Male patients predominated in Cho Ray study with the ratio to women as 2.33/1, greater 
than in studies of Choy et al. (1.67/1) and Belani et al. (2/1). However, it was relatively 
lower than in studies of Huber (6.63/1) and Yamamoto (6.75/1).  
In most studies, Karnofsky score was utilized to assess the performance status of 
participants. The majority of patients in this current study had good baseline performance 
status score of 90 to 100 (71.6%). It was similar to German trial (70%) and favorable than 
other studies, from 44.2% to 47.5%. Patients with KPS 70 were rarely seen with 
percentage from 2.2 to 6% in several studies.  
About histological characteristics, adenocarcinoma (ADC) and its subtype 
(bronchioloalveolar carcinoma - BAC) predominated with percentage of 75% and 15%, 
respectively. There were only 10% squamous cell carcinomas in our study.  
In contrast, squamous cell carcinoma (SCC) was more common in Western trials. For 
example, the frequency of SCC patients in studies of Choy et al., Belani et al., Huber et al., 
Yamamoto et al. ranged from 40.2% to 62.6%. In addition, large cell carcinoma occupied 
from 4% to 22.5% in these studies but no case was seen in Cho Ray. 
About staging, there were fewer patients with stage IIIB in Cho Ray trial (43.3%) 
compared with other studies such as Vokes et al. (46%), Belani et al. (62%), Yamamoto et 
al. (66.7%), Choy et al. (70%) and Huber et al. (88.9%). 
 
4.2.2. Treatment-related adverse events  
Hematological toxicities 
As shown in Table 4.3, most hematological adverse events in our current data were in 
grade 0–2. Grade 3 or worse hematological toxicities during concurrent chemo-
radiotherapy were infrequently with leukopenia (11.7%), anemia (3.3%) and neutropenia 
(3.3%). Grade 3 or worse thrombocytonia, liver or renal function adverse events was not 
recorded.  
These figures confirmed the favorable hematological toxicity profile of concurrent chemo-
radiation alone with lower dose of weekly paclitaxel (45mg/m
2
) in compared to other 
studies in similar fashion combined with induction or consolidation chemotherapy and 
greater dose of paclitaxel. With the same dose of paclitaxel as our trial (45mg/m
2
), 
hematological toxicities seemed much more severe in the study of Belani et al. Grade 3 or 
62 
 
worse granulocytopenia was seen in 26% of patients with concurrent chemo-radiotherapy 
and 12% in chemotherapy consolidation arm (Belani et al 2005). 
Vokes et al. also reported more grade 4 toxicities recorded in patients with the arm of 
induction chemotherapy and concurrent chemo-radiation (40%) compared to patients with 
the arm of concurrent chemo-radiotherapy only (26%) (Vokes et al. 2007). 
Meanwhile, grade 3 or 4 esophagitis in German study occurred only in 12.8% of patients in 
the chemo-radiotherapy arm and in 6.5% of patients in the alone radiotherapy arm. Low 
rates of toxicities in this trial might be related to the using of paclitaxel monotherapy 
combining to radiotherapy (Huber et al. 2006). 
Table 4.4. Grade 3-4 toxicities in selected studies of concurrent chemo-radiotherapy 
Grade 3-4 
toxicities (%) 
Choy et 
al. 
(n=37) 
Belani et 
al. 
(n=92) 
Huber et 
al. 
(n=99) 
Vokes et 
al. 
(n=161) 
Yamamoto 
et al. 
(n=147) 
Cho Ray 
(n=60) 
Anemia  13.5 10 0 5 6.1 3.3 
Leukopenia  51.3 51 2 36 46.9 11.7 
Neutropenia  37 26 0 15 23.1 3.3 
Thrombocytopenia  7.7 12 0 - 5.4 0 
Nausea/Vomiting  8.1 7 3 - 3.4 1.7 
Fatigue/Anorexia  - - 3 20 1.4 23.3 
Weight loss  8.1 - 1 - - 0 
Dyspnea/Lung  21.6 16 1 14 2.7 6.6 
Esophagitis  45.9 28 12.8 32 7.5 23.4 
 
Non-hematological toxicities 
About radiation-related toxicities, dysphagia and cough/ dyspnea were two most common 
in all studies with concurrent chemo-radiotherapy. Grade 3 or 4 dysphagia or odynophagia 
due to esophagitis was observed in 23.3% of patients in our trial. This toxicity was usually 
brief and self-limiting. Despite substantial acute toxicities with concurrent regimen, long-
term or late toxicity did not appear to be common. There was only one patients developed 
late esophageal toxicity and needed dilation of the esophagus. Grade 3 or worse cough/ 
dyspnea occurred only in 6.7% of patients but there were two patients developed fatal 
dyspnea after treatment. This could be due to treatment-related pneumonitis or disease 
progression. 
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In general, the frequency of esophagitis in current study seemed rather low and tolerable 
compared with concurrent chemo-radiotherapy combined with induction/consolidation 
chemotherapy in other trials. In study of CALGB 39801, severe dysphagia and dyspnea 
were observed in 32% and 14% of patients with concurrent chemo-radiation in 
respectively (Vokes et al. 2007). 
Belani et al. observed that esophagitis was the most common loco-regional toxicity and 
more pronounced (28%) with the administration of concurrent chemo-radiotherapy (Belani 
et al. 2005). 
The West Japan Thoracic Oncology Group also reported higher rates of severe esophagitis 
(33.3%) in arm of weekly paclitaxel/carboplatin for 6 weeks plus radiotherapy of 60Gy, 
followed by two courses of paclitaxel/carboplatin (Yamamoto et al. 2010). 
Treatment adherence 
93.3% patients in our study received the full dose of radiotherapy and 91.7% of patients 
received the planned six cycles of concurrent chemotherapy. The mean treatment time was 
6.3 weeks in which 60% of patients had interruptions with average time of 4.1 days due to 
machine break-down or public holidays. For chemotherapy administration, 38.3% had 
delayed doses during the chemotherapy cycles and 18.3% had a dose reduction of 
chemotherapy.  
Meanwhile, in the study of Belani et al., there were only 69 - 74% of patients completing 
all cycles of chemotherapy and 70 - 81% patients received fully the scheduled radiotherapy 
dose (Belani et al 2005). 
 
4.2.3. Response rates  
The overall response rates of 56 assessable patients at Cho Ray hospital were 57.2%, 
including 3 patients of complete response (5.4%) and 29 patients of partial response 
(51.8%). These figures were encouraging comparable with results of German trial in which 
patients in arm of chemo-radiotherapy had overall response rate of 46.4%. This trial also 
reported significant great number of patients with complete responses (12.1%) in 
concurrent chemo-radiotherapy arm. However, the number of deceased patients within the 
first 3 months in this arm was relatively high (8.1%) (Huber et al. 2006).  
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Choy et al. reported an impressive response rate of 75.7% in assessable 37 patients. Of 
these, 16.2% had a complete response, 59.5% had a partial response, 10.8% had 
progressive disease, and 13.5% had stable disease (Choy et al. 1998).  
In Japanese study, the objective response rate was 63.3% in patient group of concurrent 
and consolidation treatment with 3.4% of complete responses and 59.9% of partial 
responses (Yamamoto et al. 2010). 
Table 4.5. Response rates in selected studies of concurrent chemo-radiotherapy 
Response rates (%) Huber et al. 
(n=99) 
Yamamoto et al. 
(n=147) 
Choy et al. 
(n=37)  
Cho Ray 
(n=56) 
Complete responses (CR) 12 (12.1) 5 (3.4) 6 (16.2) 3 (5.4) 
Partial responses (PR) 34 (34.3) 88 (59.9) 22 (59.5) 29 (51.8) 
Stable diseases (SD) 15 (15.2) 32 (21.8) 5 (13.5) 15 (26.8) 
Progression diseases (PD) 28 (28.3) 16 (10.9) 4 (10.8) 9 (16) 
Died  8 (8.1) - - - 
No information  4 (4) 6 (4.1) - - 
Overall response rates 
(CR+PR) 
46 (46.4) 94 (63.3) 28 (75.7) 32 (57.2) 
 
4.2.4. Survival time 
As previously stated, the combined modality regimen was considered as “standard of care” 
for patients with locally advanced NSCLC. CALGB 8433 was the first major randomized 
clinical trial to show the significant survival advantage of the combination of sequential 
chemotherapy and radiotherapy with median survival of 13.7 months (Dillman et al. 1990). 
Therefore, this median was usually used as the historical control. The results of the present 
study revealed the median overall survival of 14.4 months, comparing favorably with this 
reference figure.  
As one of the first phase III trial to address the role of induction chemotherapy in the 
context of concomitant chemo-radiotherapy for stage III NSCLC, Vokes et al. reported that 
the addition of induction chemotherapy failed to provide a survival benefit over concurrent 
therapy alone. The median survival time was 12 months in regimen of concomitant chemo-
radiotherapy only, not significantly different in comparing with survival of 14 months in 
induction chemotherapy and combining treatment arm (Vokes et al. 2007).  
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Comparing three different weekly schedules of the carboplatin/paclitaxel regimen for 
patients with advanced NSCLC, the best median overall survival (16.3 months) was 
reported for arm of maintenance therapy after combination treatment (Belani et al. 2005). 
As a phase III study, Huber et al. showed a favorable median survival time in patients 
receiving simultaneous chemo-radiotherapy (18.7 months) comparing to radiotherapy 
alone (14.1 months) (Huber et al. 2006).  
As one of the most recent trial, Yamamoto et al. reported the median survival time in three 
different of regimens including second generation regimens at full doses or the third 
generation regimens at reduced doses were 20.5, 19.8, and 22.0 months in respectively 
(Yamamoto et al. 2010). This survival advantage was definitely related to several factors, 
including better patient selection (especially the inclusion of positron emission tomography 
scan and brain magnetic resonance imaging in the initial work-up) and technical 
improvements in radiotherapy (Blackstock et al. 2007). 
Table 4.6. Survival time in selected studies of concurrent chemo-radiotherapy  
References No. of Pts Regimen of 
treatment 
Median Survival 
Time (months) 
P-value 
Choy et al. 40 CCRT – CT cons 20.5 - 
Belani et al.  
91 IndCT – RT 13.0 
Not significant 74 IndCT- CCRT 12.7 
92 CCRT – CT cons 16.3 
Huber et al. 
113 IndCT – RT 14.1 
0.091 
99 IndCT – CCRT 18.7 
Vokes et al.   
161 CCRT 12 
0.3 
170 IndCT – CCRT 14 
Yamamoto et al. 
146 CCRT –CTcons (A) 20.5 
0.392 (A vs B) 
0.876 (A vs C) 
147 CCRT – CT cons (B) 19.8 
147 CCRT – CTcons (C) 22 
Cho Ray  60 CCRT 14.4 - 
Abbreviations: CCRT, concurrent chemo-radiotherapy; Ind, induction; CT, chemotherapy; cons, 
consolidation; A - MVP: Mitomycin C, Vindesine, Cisplati; B – Irinotecan, Carboplatin; C – Paclitaxel, 
Carboplatin. 
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Prognostic factors  
Predefined subgroups of patients were analyzed in this study to determine whether the 
effect of concomitant chemotherapy varied across subgroups. In terms of survival or 
progression-free survival, the effect of concomitant chemotherapy appeared greater in 
patients with female gender, age group from 60-69 years old, earlier stage, good baseline 
performance status and weight loss under 5%. Among these, pretreatment performance 
status and weight loss were considered as two significant predictive factors in our trial.  
In a meta-analysis included 1764 patients, Auperin et al. suggested the effect of 
concomitant chemotherapy appeared greater in patients with stage IIIA disease than in 
those with stage IIIB, both for survival and for event-free survival (Auperin et al. 2006). 
 
4.2.5. Pattern of failures 
After median follow-up time of 12.7 months, 38.3% of patients had distant metastases and 
33.3% had local recurrences. Local recurrences were more common in squamous cell 
carcinoma (66.7%). In contrast, there were more distant metastatic cases in 
adenocarcinoma (42.2%) and bronchioloalveolar carcinoma (44.4%). Brain was the most 
common site for distant failures (56.5%). Other common metastatic sites included bony 
lesions (39.1%), liver (17.4%) and lungs (13%). 
In study of Choy et al., the primary tumor site failures were seen in 53% of the patients 
while distant metastasis alone was the first site of failure in 46.6% of the patients. Like our 
finding, brain was also the most common site for distant metastases (50%) (Choy et al. 
1998).  
Huber et al. reported that relapse rate was less frequent in the chemo-radiotherapy group 
compared with the radiotherapy alone group (65.7% versus 85.9%, respectively; P<0.001). 
The authors also realized that there was no difference in the distribution of relapse 
locations between two arms of treatment (Huber et al. 2006). 
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5. SUMMARY 
 
This chapter revisits the aims, rationale and approach of the study, and summarizes the 
principal findings of the research. The next section considers the strengths and limitations 
of the studies.  
5.1. Revisiting the rationale, aims and the approach of the thesis 
In Vietnam, non-small cell lung cancer (NSCLC) occupied around 80-85% of lung cancer. 
Radiotherapy combined with chemotherapy sequentially or concurrently was considered a 
suitable option for many patients with inoperable stage III NSCLC. However, due to the 
shortage in radiotherapy equipment in many cancer centers, many patients with this stage 
were treated with palliative intent such as chemotherapy alone or supportive care only. 
That is the main reason for setting up a study to treat the patients with stage III NSCLC at 
Cho Ray hospital by concomitant chemo-radiotherapy. The study aimed to investigate the 
efficacy of combining radiotherapy and chemotherapy concurrently by analyzing the 
median survival time, the progression-free survival, the overall survival and the response 
rate in the study population. It also aimed to assess the safety and tolerability of patients 
receiving concomitant chemo-radiotherapy.  
Patients with stage III non-small lung cancer who satisfied the selection criteria were 
accrued into this prospective study. The study cohort was selected from all patients with 
locally advanced non-small cell lung cancer who presented to the Department of 
Oncology, Cho Ray hospital, Ho Chi Minh city, Vietnam from 1
st
 March 2009 to 1
st
 March 
2012.  
Following entry into the study, patients were planned to receive weekly paclitaxel with 
carboplatin concurrent with radiotherapy of 60Gy in 30 fractions for six consecutive 
weeks. The paclitaxel was administered at 45mg/m
2
 intravenously (1 hour) and the 
carboplatin being given at a formula time versus concentration curve (AUC) of two 
intravenously (30 minutes) following administration of paclitaxel. Clinical details of all 
patients were recorded prospectively and included name, gender, age, personal and family 
histories, social habits like smoking, histology, clinical presentation, performance status, 
weight loss in previous three months, details of treatment regimen, toxicities and outcome 
of treatment. 
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5.2. Summary of the principal findings 
The subtypes of histology in this series included adenocarcinoma (75%), 
bronchioloalveolar carcinoma (15%) and squamous cell carcinoma (10%). There were 
70% of males and 30% of females and mean age of patients was 58 years. Smokers 
occupied 88% of male patients and 5.6% of female patients. Most of patients (71.6%) had 
KPS score from 90-100. 66.7% of patients had no weight loss or weight loss under 5% of 
their normal weight in previous three months.  
For lung tumor characteristics, the ratio of right to left-sided primary tumors was 1.5/1. 
The great proportion of tumors (43.4%) located in the upper lobes of the lung, 25% in the 
lower lobes and 28.3% in the main bronchi. Common sites of lymph nodes involvement in 
descending order were para-aortic (46.7%), para-tracheal (17.4%), sub-carinal (13.3%) and 
sub-aortic (10.7%) regions. The frequency of patients with stage IIIA and IIIB were 56.7% 
and 43.3%, respectively. 
For treatment administration, 93.3% received radiotherapy of 60Gy and 91.7% completed 
6 cycles of chemotherapy as planned in protocol. The reasons for not completing treatment 
were treatment-related complication and patient refusal.  
Common hematological toxicities in any grade consisted of leukopenia (65%), anemia 
(61.7%) and neutropenia (38.3%) and thrombocytopenia (8.3%). Grade 3 or 4 
hematological toxicities occurred in 3.3% of anemia, 11.7% of leukopenia and 3.3% of 
neutropenia.  
Common non-hematological side-effects included esophagitis (66.7%), fatigue/anorexia 
(80%), dermatitis (48.3%), alopecia (41.7%), weight loss (40%) and nausea/vomiting 
(28.3%). Grade 3 or 4 non-hematological toxicities were composed of 
dysphagia/odynophagia due to esophagitis (23,3%), fatigue/anorexia (23,3%), leukopenia 
(11.7%) and cough/dyspnea (6.6%). 
The objective response rate was 57.2%, including 5.4% of complete responses and 51.8% 
of partial responses, according to RECIST criteria. With the follow up time of 12.7 
months, the median of overall survival and progression-free survival were 14.4 months and 
10.8 months in respectively. The median of progression-free and overall survival time 
trended better in gender of female, age group from 60-69 years old, subtype of 
bronchioloalveolar carcinomas and patients with stage IIIA. Pretreated performance status 
and weight loss were two significant prognostic factors. 
69 
 
5.3. Strengths and limitations of the study 
One of the strengths of this study was the completeness of the data set. From the 
perspective of a clinical study to evaluate efficacy of concurrent chemo-radiotherapy alone 
with regimen of weekly paclitaxel combined carboplatin, the sample size of the current 
study was relatively small in comparison to other multicenter studies. Consequently, the 
data should be considered to be explanatory and comparing to similar studies, rather than 
definitive. A larger sample size should be evaluated to validate our results.  
Another limitation of this study was in the patient selection. Due to the required 
commitment and intense procedures, patients with poor economic conditions and living far 
from Ho Chi Minh city tended to decline participation.  
Besides, approximately 10 - 30% of patients with non-metastatic NSCLC as determined by 
conventional imaging might be found to have distant metastases with more modern 
diagnostic tools such as MRI of brain and positron emission tomography (Pfister et al. 
2004). This was also our limitation in patient selection in which most were not staged with 
positron emission tomography scan and brain magnetic resonance imaging. This might 
explain for several early distant metastasis cases in our report. 
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6. THESEN 
 
1. From 1/3/2009 to 1/3/2012, 821 men and 337 women were treated due to lung 
cancers at Department of Oncology, Cho Ray hospital, Ho Chi Minh city, Vietnam.  
63.9% of patients were between 45 to 64 years old with median age of 56 years old 
with a range of 20 – 87 years. 
2. 64.3% of the patients had pathology of adenocarcinomas while other subtypes were 
less infrequently such as squamous cell carcinomas (11.3%), small cell lung cancer 
(4.9%) and large cell carcinomas (0.8%). In non-small cell lung cancer (NSCLC), 
38.4% of the patients were admitted in locally advanced stages and 51.1% in 
metastatic stages. 
3. Among 423 stage III NSCLC patients, there were 60 patients (14.2%), including 42 
men and 18 women, received weekly Paclitaxel – Carboplatin combined 
concurrently with radiotherapy to 60Gy in 6 weeks. 
4. In this group, 71.6% of the patients had Karnofsky performance status (KPS) score 
from 90 to 100 and 66.7% had no weight loss or weight loss under 5% in previous 
3 months. Pathological subtypes were composed of 75% of adenocarcinomas 
(ADC), 15% of bronchiolo-alveolar carcinomas (BAC) and 10% squamous cell 
carcinomas (SCC). According to 6
th
 edition of IASLC classification, 56.7% of the 
patients were classified as stage IIIA and 43.3% as stage IIIB. 
5. For treatment administration, 93.3% of the patients were irradiated to total dose of 
60Gy and 91.7% completed six cycles of chemotherapy as protocol. 
6. Common toxicities in any grades were fatigue/anorexia (80%), esophagitis 
(66.7%), leukopenia (65%), anemia (61.7%) and neutropenia (38.3%). Common 
grade 3 or 4 toxicities included esophagitis (23.3%), fatigue/anorexia (23.3%), 
leukopenia (11.7%) and cough/dyspnea (6.6%). 
7. Overall responses rate was 57.2%, including 5.4% of complete responses and 
51.8% of partial responses. 26.8% of the patients had stable diseases and 16% had 
progressive disease according to RECIST criteria. 
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8. With median time of follow up as 12.7 months, 36.7% patients alive, 3.3% patients 
missing of follow-up and 60% patients deceased. The median of overall survival 
and progression-free survival were 14.4 months and 10.8 months in respectively. 
9. In multivariate analysis, the time to progression and overall survival time trended to 
be better in gender of female, age of 60-69 years old, bronchioloalveolar carcinoma 
and stage IIIA, however, pretreatment performance status and weight loss at 
baseline were two only significant prognostic factors. 
10. The strength of this study was the completeness of the data although the sample 
size was not a huge number in comparison to other multicenter studies. 
Consequently, the data should be considered to be explanatory and comparing to 
similar studies, rather than definitive. A larger sample size should be evaluated to 
validate our results.  
11. A limitation of this study was in the patient selection with no patients with poor 
economic conditions and living far from Ho Chi Minh city coming to participation. 
An additional limitation of this study was the staging procedure in which most of 
patients were not staged with positron emission tomography scan and brain 
magnetic resonance imaging. 
12. This study proved that the regimen of weekly paclitaxel – carboplatin 
chemotherapy combined concurrently with radiotherapy was relatively safe and 
feasible to do in Vietnam although the careful selection of patients and using of 
comprehensive staging procedure were necessary. 
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8. APPENDICES 
Appendix A. WHO Histological Classification Of Lung Cancer (Travis et al. 1999) 
EPITHELIAL TUMORS (MALIGNANT) 
Squamous cell carcinoma 
   Variants 
   Papillary 
   Clear cell 
   Small cell 
   Basaloid 
Small cell carcinoma 
   Variant 
   Combined small cell carcinoma 
Adenocarcinoma 
   Acinar 
   Papillary 
   Bronchioloalveolar carcinoma 
   Nonmucinous (Clara cell/type II pneumocyte) type 
   Mucinous (goblet cell) type 
   Mixed mucinous and nonmucinous (Clara cell/type II pneumocyte and goblet cell) type, or 
indeterminate cell type 
   Solid adenocarcinoma with mucin formation 
   Adenocarcinoma with mixed subtypes  
Variants 
   Well-differentiated fetal adenocarcinoma 
   Mucinous adenocarcinoma 
   Mucinous cyst adenocarcinoma 
   Signet-ring adenocarcinoma 
   Clear cell adenocarcinoma 
Large cell carcinoma 
   Variants 
   Large cell neuroendocrine carcinoma 
   Combined large cell neuroendocrine carcinoma 
   Basaloid carcinoma 
  Lymphoepithelioma-like carcinoma 
   Clear cell carcinoma 
   Large cell carcinoma with rhabdoid phenotype 
Adenosquamous carcinoma 
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements 
   Carcinomas with spindle or giant cells 
   Pleomorphic carcinoma 
   Spindle cell carcinoma 
   Giant cell carcinoma 
   Carcinosarcoma 
   Pulmonary blastoma 
   Others 
Carcinoid tumors 
   Typical carcinoid 
   Atypical carcinoid 
Carcinomas of salivary gland type 
   Mucoepidermoid carcinoma 
   Adenoid cystic carcinoma 
   Others 
Unclassifiedcarcinoma 
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Appendix B. International Staging System For Non-Small Cell Lung Cancer (6
th
 
Edition) 
PRIMARY TUMOR 
Tx Primary tumor proven by the presence of malignant cells in thebroncho-pulmonary secretions 
but not visible on radiographic or endoscopic examination 
T0 No primary tumor detected 
Tis Carcinoma in situ 
T1 Tumor measuring 3 cm or less in its largest dimension surrounded by lung or visceral pleura, 
or endobronchial tumor, proximal to one lobar bronchus 
T2 Tumor measuring more than 3 cm in its greatest dimension or extension to the visceral pleura 
or atelectasis or obstructive pneumopathy of less than one lung or lobar endobronchial tumor 
or tumor of one principal bronchus at more than 2 cm from the carina 
T3 Tumor of the apex or endobronchial tumor of one principal bronchus at less than 2 cm from 
the carina but not invading it or atelectasis or tumor in any size with direct extension to the 
adjacent structures (to the chest wall, to the mediastinal pleura). Extension to the pericardium 
pariental layer or to the diaphragm or to the mediastinal fat or to phrenic nerve 
T3a Atelectasis or obstructive pneumopathy of one entire lung without other criterion for T3 
T3b If other criterion/criteria present for a T3 
T4 Macroscopic or histological extension to the mediastinum, or heart, or great vessels, or 
trachea, or oesophagus, or vertebral body or carina, or tumor with a malignant pleural or 
pericardial effusion, or recurrent involvement, or invasion of the homolateral visceral or 
parietal pleura which cannot be a result of direct spread of the tumor, or multiple neoplastic 
nodules in the same lobe of the lung. 
T4a All T4 except T4b 
T4b Invasion of carina or presence of a malignant pleural effusion 
 
REGIONAL LYMPH NODES 
N0 No metastasis to regional lymph node 
N1 Metastasis to hilar lymph nodes or to peribronchialhomolateral (interlobar, lobar, segmental) 
or to both (including direct extension) 
N2 Metastasis to the homolateralmediastinal lymph node or subcarinal node 
N3 Metastasis to contralateral mediastinal lymph nodes, or to homolateral or contralateral 
scalene, or sub-clavicular lymph nodes or to contralateral hilar lymph nodes 
N3a Metastasis in the controlateral (hilar or mediastinal) lymph nodes 
N3b Metastasis in the sub-clavicular fossae or scalene lymph nodes 
DISTANT METASTASES 
MX Presence of distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases present 
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STAGE GROUPING 
Stage T N M 
Occult X 0 0 
IA 1 0 0 
IB 2 0 0 
IIA 1 1 0 
IIB 2 1 0 
 3 0 0 
IIIA Any except T4 2 0 
 3 1 0 
IIIB Any 3 0 
 4 Any 0 
IV Any Any 1 
 Several nodules in different lobes 
 
Appendix C. Classification Of Common Toxicities Criteria (National Cancer Institute 
Version 2.0) 
Toxicity 0 1 2 3 4 
Hemoglobin 
(Hgb) 
WNL < LLN - 10.0 g/dl 
 
8.0 - < 10.0 g/dl 
 
6.5 - < 8.0 g/dl 
 
< 6.5 g/dl 
 
Leukocytes 
(total WBC) 
WNL < LLN - 3.0 x 
10
9
/L 
 
2.0 - < 3.0 x 
10
9
/L 
 
1.0 - < 2.0 x 
10
9
/L 
 
< 1.0 x 10
9
/L 
 
Neutrophils/ 
granulocytes 
(ANC) 
WNL 1.5 - <2.0 x 
10
9
/L 
 
1.0 - <1.5 x 10
9
/L 
 
0.5 - <1.0 x 
10
9
/L 
 
< 0.5 x 10
9
/L 
 
Platelets WNL < LLN - <75.0 x 
10
9
/L 
 
50.0 - < 75.0 x 
10
9
/L 
 
10.0 - < 50.0 x 
10
9
/L 
 
< 10.0 x 10
9
/L 
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Toxicity 0 1 2 3 4 
SGOT (AST)  
(serum glutamic 
oxaloacetic 
transaminase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x 
ULN 
> 20.0 x ULN 
SGPT (ALT)  
(serum glutamic 
pyruvic trans-
aminase) 
WNL > ULN - 2.5 x 
ULN 
> 2.5 - 5.0 x ULN > 5.0 - 20.0 x 
ULN 
> 20.0 x ULN 
Creatinine WNL > ULN - 1.5 x 
ULN 
> 1.5 - 3.0 x ULN > 3.0 - 6.0 x ULN > 6.0 x ULN 
Alopecia normal mild hair loss pronounced hair 
loss 
- - 
Radiation 
dermatitis 
none faint erythema or 
dry desquamation 
moderate to brisk 
erythema or a 
patchy moist 
desquamation, 
mostly confined to 
skin folds and 
creases; moderate 
edema 
confluent moist 
desquamation, 
1.5 cm diameter, 
not confined to 
skin folds; pitting 
edema 
skin necrosis or 
ulceration of 
full thickness 
dermis; may 
include 
bleeding not 
induced by 
minor trauma 
or abrasion 
Anorexia none loss of appetite Oral intake 
significantly 
decreased 
requiring IV 
fluids 
requiring 
feeding tube or 
parenteral 
nutrition 
Nausea None able to eat Oral intake 
significantly 
decreased 
no significant 
intake, requiring 
IV fluids 
- 
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Toxicity 0 1 2 3 4 
Dysphagia, 
esophagitis, 
odynophagia 
(painful 
swallowing) 
none mild dysphagia, 
but can eat 
regular diet 
 
 
 
 
dysphagia, 
requiring 
predominantly 
pureed, soft, or 
liquid diet 
dysphagia, 
requiring IV 
hydration 
complete 
obstruction 
(cannot 
swallow saliva) 
requiring 
enteral or 
parenteral 
nutritional 
support, or 
perforation 
Infection 
(documented 
clinically or 
microbiologi-
cally) with 
grade 3 or 4 
neutropenia 
none - - present life-threatening 
sepsis (e.g., 
septic shock) 
Infection with 
unknown ANC 
none - - present life-threatening 
sepsis (e.g., 
septic shock) 
Cough absent mild, relieved by 
non-prescription 
medication 
requiring narcotic 
antitussive 
severe cough or 
coughing spasms, 
poorly controlled 
or unresponsive to 
treatment 
- 
Dyspnea  
(shortness of 
breath) 
normal - dyspnea on 
exertion 
dyspnea at normal 
level of activity 
dyspnea at rest 
or requiring 
ventilator 
support 
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Appendix D. Performance Status Karnofsky Grading 
100 Normal, no complaints, no evidence of disease 
90  Able to carry on normal activity, minor signs or symptoms of disease 
80 Normal activity with effort, some signs or symptoms of disease  
70 Cares for self, unable to carry on normal activity or to do active works. 
60 Requires occasional assistance but is able to care for most needs. 
50 Requires considerable assistance and frequent medical care. 
40 Disabled, requires special care and assistance 
30 Severely disabled, hospitalisation is indicated although death not imminent  
20 Very sick, hospitalisation necessary, active supportive treatment necessary 
10 Moribund, fatal processes progressing rapidly 
0 Dead  
Appendix E. Response Evaluation Criteria In Solid Tumors (RECIST) 
The evaluation of target lesions will be performed using the sum of the longest diameter (LD) for 
all of these lesions. The LD will be calculated and reported as the baseline sum LD will be used as 
reference to further characterize the objective tumor response of the measurable dimension of the 
disease as follows: 
Evaluation of target lesions 
Complete Response (CR): Disappearance of all target lesions 
Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking 
as reference the baseline sum LD 
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking 
as reference the smallest sum LD recorded since the treatment started 
or the appearance of one or more new lesions 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum LD since the 
treatment started 
 
87 
 
CURRICULUM VITAE 
 
Personal information 
 Name:   Le 
 First name:  Tuan Anh 
 Date of birth:  28.10.1975 
 Place of birth:  Long An Province, Vietnam 
 Marital status:  Married 
 
School education 
1981 – 1985  Minh Dao Primary School, Ho Chi Minh city, Vietnam 
1986 – 1989  Hong Bang Secondary school, Ho Chi Minh city, Vietnam  
1990 – 1992  Le Hong Phong High-school, Ho Chi Minh city, Vietnam 
 
Training education 
1993 – 1999                Medical student, University of Medicine and Pharmacy at 
Ho Chi Minh city, Ho Chi Minh city, Vietnam. 1999, 
graduated with Degree of Medical Doctor, grade: Excellent. 
3.2002 – 7.2002          Study at Department of Radiation Oncology, National 
University Hospital, Singapore. 
10.2002 – 1.2003        Study at William Buckland Radiotherapy Center, The Alfred 
Hospital, Melbourne, Australia. 
2003 – 2005 Master of Medicine, University of Medicine and Pharmacy 
atHo Chi Minh city, Ho Chi Minh city, Vietnam. 2005, 
graduated with Master Degree of Medicine, Specialty of 
Oncology. 
 4.2005 – 6.2005  Study at Universität Leipzig, Klinik fur Strahlentherapie. 
2011, 2012, 2013 Study at Klinik und Poliklinik fur Strahlentherapie, Rostock. 
 
Working experiences 
2002 – 2008 Deputy Head, Department of Oncology, Cho Ray hospital,  
Ho Chi Minh city, Vietnam. 
2009 – now  Head, Department of Oncology, Cho Ray hospital, Ho Chi 
Minh city, Vietnam. 
 
